Tristar Wellness Solutions (TWSI) Inactive 10-K16 Apr 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Apr. 15, 2014	Jun. 30, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'TRISTAR WELLNESS SOLUTIONS, INC.	'	'
Entity Central Index Key	'0001109153	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	23,041,713	'
Entity Public Float	'	'	$34,821,237
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Assets	'	'
Cash and cash equivalents	$193	$11
Accounts receivables, net	638	'
Prepaid expenses and other	178	'
Other receivables	1,500	'
Inventories, net	1,144	12
Total current assets	3,653	23
Property and equipment, net	997	1
Intangible assets, net	867	'
Other non-current assets	41	'
Total non-current assets	1,905	1
TOTAL ASSETS	5,558	24
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	1,321	33
Accounts payable and accrued expenses due to related parties	973	285
Current liabilities related to assets sold	1,500	'
Short-term notes (net of debt discount $497 and $0 as of December 31, 2013 and 2012, respectively)	714	50
Short-term notes - related party	3,970	525
Convertible notes	356	'
Deferred revenue	306	'
Total current liabilities	9,140	893
Non-current Liabilities	'	'
Deferred revenue, net of current portion	48	'
Total non-current liabilities	48	'
TOTAL LIABILITIES	9,188	893
STOCKHOLDERS' DEFICIT	'	'
Convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 5,621,667 and 6,120,000 shares issued and outstanding as of December 31, 2013 and 2012, respectively	6	6
Common stock; $0.0001 par value; 50,000,000 shares authorized; 22,041,713 and 41,032 shares issued and outstanding as of December 31, 2013 and 2012, respectively	2	'
Additional paid-in capital	18,823	8,939
Other Comprehensive Loss	-19	'
Accumulated deficit	-22,442	-9,814
TOTAL STOCKHOLDERS' DEFICIT	-3,630	-869
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$5,558	$24

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current liabilities	'	'
Short-term notes	$497	$0
STOCKHOLDERS' DEFICIT	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	10,000,000	10,000,000
Convertible preferred stock, shares issued	5,621,667	6,120,000
Convertible preferred stock, shares outstanding	5,621,667	6,120,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	22,041,713	41,032
Common stock, shares outstanding	22,041,713	41,032

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements Of Operations	'	'
Sales Revenue	$3,776	'
Cost of Goods Sold	3,074	'
Gross Profit	702	'
Operating expenses:	'	'
General and administrative	7,331	999
Sales, marketing and development expenses	2,462	700
Amortization on intangible assets	59	84
Impairment of intangible assets	15	'
Total operating expenses	9,867	1,783
Loss from operations	-9,165	-1,783
Other Income and (expenses)	'	'
Interest expense	-2,609	-35
Gain on sale of assets and liabilities	2	'
Inducement expense	-802	'
Other	-54	'
Total other income and (expenses)	-3,463	-35
Loss for the period from continuing operations	-12,628	-1,818
Loss for the period from discontinued operations	'	-430
Net loss	-12,628	-2,248
Other comprehensive loss	'	'
Foreign currency translation	-19	'
Total comprehensive loss	($12,647)	($2,248)
Continuing operation	'	'
Loss per share	($0.43)	($44.32)
Diluted loss per share	($0.43)	($44.32)
Discontinued operations	'	'
Loss per share	$0	($10.48)
Diluted loss per share	0	-10.48
Total	'	'
Loss per share	($0.43)	($54.79)
Diluted loss per share	($0.43)	($54.79)
Weighted average common shares outstanding	29,576,522	41,032
Diluted weighted average common shares outstanding	29,576,522	41,032

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Stockholders' Deficit (USD $)	Preferred Stock	Common Stock	Accumulated Deficit	Additional Paid-In Capital	Other Comprehensive Income/Loss	Total
In Thousands, except Share data	Preferred Stock	Common Stock	Accumulated Deficit	Additional Paid-In Capital	Other Comprehensive Income/Loss	Total
Beginning Balance, Amount at Dec. 31, 2011	$2	'	($7,565)	$5,034	$228	($2,301)
Beginning Balance, Shares at Dec. 31, 2011	1,620	41	'	'	'	'
2nd Quarter - Series C Preferred issued to founders in connection with the change of control transaction, Shares	710	'	'	'	'	'
2nd Quarter - Series C Preferred issued to founders in connection with the change of control transaction, Amount	1	'	'	-1	'	'
2nd Quarter - Issuance of Series D Convertible Preferred for the acquisition of an intangible asset, Shares	225	'	'	'	'	'
2nd Quarter - Issuance of Series D Convertible Preferred for the acquisition of an intangible asset, Amount	'	'	'	84	'	84
2nd Quarter - Issuance of Series D Convertible Preferred for the acquisition of inventory, Shares	25	'	'	'	'	'
2nd Quarter - Issuance of Series D Convertible Preferred for the acquisition of inventory, Amount	'	'	'	5	'	5
3rd Quarter - Issuance of Series D Convertible Preferred for research and development, Shares	2,000	'	'	'	'	'
3rd Quarter - Issuance of Series D Convertible Preferred for research and development, Amount	2	'	'	698	'	700
3rd Quarter - Issuance of Series D Convertible Preferred for cash, Shares	1,047	'	'	'	'	'
3rd Quarter - Issuance of Series D Convertible Preferred for cash, Amount	1	'	'	208	'	209
3rd Quarter - Issuance of Series D Convertible Preferred for services, Shares	493	'	'	'	'	'
3rd Quarter - Issuance of Series D Convertible Preferred for services, Amount	'	'	'	354	'	354
Beneficial conversion charge on short term convertible debt	'	'	'	400	'	400
Imputed interest on note payable	'	'	'	34	'	34
Spin-off of Subsidiaries	'	'	'	2,123	-228	1,895
Net loss	'	'	-2,249	'	'	-2,248
Ending Balance, Amount at Dec. 31, 2012	6	'	-9,814	8,939	'	-869
Ending Balance, Shares at Dec. 31, 2012	6,120	41	'	'	'	'
Imputed interest on note payable	'	'	'	31	'	31
1st Quarter - Issuance of warrants for services	'	'	'	688	'	688
1st Quarter - Issuance of warrants for research development	'	'	'	921	'	921
1st Quarter - Issuance of common stock in exchange for convertible notes and accrued interest, Shares	'	4,035	'	'	'	'
1st Quarter - Issuance of common stock in exchange for convertible notes and accrued interest, Amount	'	'	'	32	'	32
1st Quarter - Conversion of Series A Convertible Preferred into common stock, Shares	-215	1,075	'	'	'	'
1st Quarter - Conversion of Series A Convertible Preferred into common stock, Amount	'	'	'	'	'	'
1st Quarter - Conversion of Series C Convertible Preferred into common stock, Shares	-710	3,550	'	'	'	'
1st Quarter - Conversion of Series C Convertible Preferred into common stock, Amount	-1	1	'	'	'	'
1st Quarter - Conversion of Series D Convertible Preferred into common stock, Shares	-1,430	35,750	'	'	'	'
1st Quarter - Conversion of Series D Convertible Preferred into common stock, Amount	-1	3	'	-2	'	'
1st Quarter - Issuance of Series D Convertible Preferred for research and development and acqusition of Beute de Maman, Shares	750	'	'	'	'	'
1st Quarter - Issuance of Series D Convertible Preferred for research and development and acqusition of Beute de Maman, Amount	1	'	'	2,812	'	2,813
1st Quarter - Issuance of Series D Convertible Preferred for cash, Shares	67	'	'	'	'	'
1st Quarter - Issuance of Series D Convertible Preferred for cash, Amount	'	'	'	250	'	250
1st Quarter - Conversion of notes payable to Series D Convertible Preferred, Shares	60	'	'	'	'	'
1st Quarter - Conversion of notes payable to Series D Convertible Preferred, Amount	'	'	'	225	'	225
2nd Quarter - Issuance of common stock for cash, Shares	'	295	'	'	'	'
2nd Quarter - Issuance of common stock for cash, Amount	'	'	'	227	'	227
2nd Quarter - Issuance of warrants in conjunction with promissory notes	'	'	'	1,651	'	1,651
3rd Quarter - Cancellation of common stock in exchange for Series D convertible Preferred Stock, Shares	980	-24,500	'	'	'	'
3rd Quarter - Cancellation of common stock in exchange for Series D convertible Preferred Stock, Amount	1	-2	'	1	'	'
3rd Quarter - Issuance common stock for cash, Shares	'	100	'	'	'	'
3rd Quarter - Issuance common stock for cash, Amount	'	'	'	100	'	100
3rd Quarter - Issuance of warrants in conjunction with promissory notes	'	'	'	225	'	225
4th Quarter - Issuance common stock for debt conversion, Shares	'	1,500	'	'	'	'
4th Quarter - Issuance common stock for debt conversion, Amount	'	'	'	12	'	12
4th Quarter - Issuance common stock for cash, Shares	'	195	'	'	'	'
4th Quarter - Issuance common stock for cash, Amount	'	'	'	175	'	175
4th Quarter - Issuance warrants for accrued salaries conversion	'	'	'	1,902	'	1,902
4th Quarter - Issuance of warrants in conjunction with promissory notes	'	'	'	556	'	556
Cumulative translation adjustment	'	'	'	'	-19	-19
Adjustment for the forgiveness of accounts payable to NCP	'	'	'	78	'	78
Net loss	'	'	-12,628	'	'	-12,628
Ending Balance, Amount at Dec. 31, 2013	$6	$2	($22,442)	$18,823	($19)	($3,630)
Ending Balance, Shares at Dec. 31, 2013	5,622	22,041	'	'	'	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities	'	'
Loss for the period from continuing operations	($12,628)	($1,818)
Loss for the period from discontinued operations	'	-430
Adjustments to reconcile net profit/loss from continuing operations to net cash provided by operating activities:	'	'
Non-cash research and development expenses	3,726	700
Depreciation expenses	196	'
Inducement expenses	802	'
Amortization of debt discount	2,002	'
Issuance of series D convertible preferred stock for services	'	355
Issuance of warrants for services	688	'
Intangible asset amortization	59	84
Intangible asset impairment	15	'
Imputed interest on note payable	31	34
Accounts Receivables	15	'
Inventory	278	-7
Prepaid expenses	-22	'
Accounts payable and accruals	489	25
Other non-current assets	-18	'
Deferred revenue	-72	'
Accounts payable and accrued expenses - related party	1,866	285
Net cash used in operating activities from continuing operations	-2,573	-342
Net cash provided by operating activities from discontinued operations	'	-30
Cash flow from investing activities:	'	'
Purchase of computer equipment	'	-1
Acquisition of Hemcon	-3,139	'
Net cash used in investing activities	-3,139	-1
Cash flow from financing activities	'	'
Proceeds from issuance of short-term notes	1,646	175
Proceeds from issuance of short-term notes - related party	4,110	'
Proceeds from issuance of convertible notes - related party	50	'
Repayment of notes	-400	'
Repayment of notes - related party	-245	'
Proceeds from issuance of common stock	502	'
Proceeds from issuance of series D convertible preferred stock	250	209
Net cash generated from financing activities from continuing operations	5,913	384
Cumulative translation adjustment	-19	'
Net change in cash	182	11
Cash and cash equivalent, beginning	11	'
Cash and cash equivalent, ending	193	11
Supplemental disclosure	'	'
Interest Paid	31	'
Supplemental schedule of non-cash activities	'	'
Beneficial conversion feature on convertible debentures	'	400
Spinoff of assets and liabilities	'	2,123
Issuance of preferred shares for asset purchase option	'	784
Issuance of preferred shares for inventory	'	5
Conversion of notes payable to preferred stock	225	'
Debt discount on promissory note	2,432	'
Conversion of preferred stock to common stock	2	'
Conversion of common stock to preferred stock	2	'
Conversion of accrued salaries to warrants	1,100	'
Issuance of common stock in exchange for convertible notes and accrued interest	44	'
Adjustment for the forgiveness of accounts payable to NCP - Related Party	78	'
Acquisition of Beaute de Maman for Series D Convertible Preferred Stock	$8	'

The_Company

The Company	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Note 1. The Company	'
	Corporate History

	Tristar Wellness Solutions, Inc. (“the Company”) was incorporated on August 28, 2000 in the state of Nevada under the name “Quadric Acquisitions”. Following its incorporation, the Company was not actively engaged in any business activities. On April 25, 2001, the Company was acquired by ZKid Network Company and changed its name to ZKid Network Co. As a result, the Company became engaged in the business of providing media content for children through the use of its proprietary software.

	On April 12, 2006, the Company changed its name from "ZKid Network Co." to "EATware Corporation"; and effected a four thousand (4000) for one (1) reverse stock split.

	On May 8, 2006, the Company closed a share exchange agreement with Star Metro Group Limited, which became a wholly-owned subsidiary. As a result of the share exchange agreement, the Company became engaged in the development, production and sale of a line of biodegradable, single use, food and beverage containers.

	On November 27, 2006, the Company changed its name from “EATware Corporation” to “Star Metro Corp.” On February 26, 2007, the Company changed the name from “Star Metro Corp.” to “Biopack Environmental Solutions Inc.” This name change was effected by merging Biopack Environmental Solutions Inc., a newly incorporated and wholly-owned subsidiary that was created for this purpose, into the Company, with the Company carrying on as the surviving corporation under the name “Biopack Environmental Solutions Inc.”

	On March 27, 2007, the Company completed a share exchange with the shareholders of Roots Biopack Group Limited, a company formed under the laws of the British Virgin Islands. Under the terms of the share exchange agreement the Company acquired all of the issued and outstanding common shares of Roots Biopack Group and the Company was engaged in the development, manufacture, distribution and marketing of bio-degradable food containers and disposable industrial packaging for consumer products.

	On November 3, 2011, the People’s Court of Guandong Jiangmen Pengjiang District held a hearing relating to the Company’s landlord’s claim for unpaid rent for factory plus penalty interest and other claims. The landlord had made a claim for payment of overdue rent in the amount of RMB 1,236, penalty interest in the amount of RMB 1,068 and a claim for potential loss of income in the amount of RMB 618, for a total amount claimed of RMB 2,922 (approximately $451). At the hearing, the Court ruled that after two unsuccessful attempts to auction the factory’s assets at the minimum level set by the Court-appointed independent valuation company’s fair market assessment price, the Court set the reference value at RMB 3,613 (approximately $569) and transferred all the assets to the landlord. The landlord became legally responsible for settling all claims made by creditors, and the case was closed.

	On April 27, 2012, the holders of our preferred stock, which account for the voting control of the company, entered into an Agreement for the Purchase of Preferred Stock (the “Agreement”) by Rockland Group, LLC, a Texas limited liability company (“Rockland”), under which Rockland purchased Six Hundred Twenty Thousand (620,000) shares of the Company, Inc. Series A Convertible Preferred Stock (the “Series A Preferred Shares”), One Million Shares (1,000,000) shares of the Company Series B Convertible Preferred Stock (the “Series B Preferred Shares”) and Seven Hundred Ten Thousand (710,000) shares of the Company Series C Convertible Preferred Stock (the “Series C Preferred Shares”, and together with the Series A Preferred Shares and the Series B Preferred Shares, the “Shares”). These shares represent approximately 63% of our outstanding votes on all matters brought before the holders of our common stock for approval and, therefore, represented a change of control. The transaction closed on April 27, 2012.

	On April 27, 2012, we entered into a Subsidiary Acquisition Option Agreement (“Subsidiary Option Agreement”) with Xinghui Ltd., a Chinese entity (“Purchaser“), under which sold all the shares in the BPAC Subsidiaries to the Purchaser, effective July 11, 2012, in exchange for the Purchaser assuming all our liabilities as of April 25, 2012, which included all of the liabilities and obligations of ours except for a $400 principal amount convertible note that was owed to Trilane Limited as of April 27, 2012. As a result of us exercising our rights under the Subsidiary Option Agreement, we no longer own the BPAC Subsidiaries, including any of their assets or liabilities.

	On June 25, 2012, the Company entered into a License and Asset Purchase Option Agreement (the “Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), under which the Company, acquired the exclusive license to develop, market and sell, NCP’s Beaute de Maman™ product line, which is a line of skincare and other products specifically targeted for pregnant women. In addition, the Company acquired the exclusive license rights to develop, market and sell NCP’s formula being developed for itch suppression, which would be sold as an over-the-counter product, if successful. In exchange for these license rights the Company agreed to issue NCP 225,000 shares of the Company’s Series D Convertible Preferred Stock. This transaction closed on June 26, 2012. Additionally, under the Agreement, in connection with its license rights and to ensure the Company could fulfill any immediate orders timely, the Company purchased all existing finished product of the Beaute de Maman™ product line currently owned by NCP. In exchange for the inventory the Company agreed to issue NCP 25,000 shares of Series D Convertible Preferred Stock. Each share is convertible into twenty five shares of the Company’s common stock.

	On July 11, 2012, the Company entered into a Marketing and Development Services Agreement (the “Marketing Agreement”) with InterCore Energy, Inc. (“ICE”). Under the Marketing Agreement the Company was retained to market and develop certain assets referred to as the Soft & Smooth Assets held by ICE. The Soft & Smooth Assets include all rights, interests and legal claims to that certain invention entitled “Delivery Device with Invertible Diaphragm” which is a novel medical applicator that is capable of delivering medicants and internal devices within the body in an atraumatic fashion (without producing injury or damage). In addition, the Company was also granted the exclusive option, in its sole discretion, to purchase the Soft & Smooth Assets from ICE for warrants to purchase One Hundred Fifty Thousand (150,000) shares of its common stock at One Dollar ($1) per share, with a four (4) year expiration period. On February 12, 2013, the Company entered into an Asset Purchase Agreement (the “HLBCDC Asset Purchase Agreement”) with HLBC Distribution Company, Inc. (“HLBCDC”), under which we exercised our option to purchase the Soft & Smooth Assets held by HLBCDC, which had acquired the Soft & Smooth Assets from ICE. In exchange for the Soft and Smooth Assets we agreed to issue to HLBCDC warrants enabling HLBCDC to purchase One Hundred Fifty Thousand (150,000) shares of its common stock at One Dollar ($1) per share, with a four (4) year expiration period. In April 2012, the Company changed its name from “Biopack Environmental Solutions, Inc.” to “Tristar Wellness Solutions, Inc.” This name changes was effected by the agreement between the holders of its preferred stock, which account for the voting control of the Company with Rockland Group, LLC (“Rockland”), under which Rockland purchased shares of TriStar Wellness Solutions, Inc. These shares represent approximately 63% of its outstanding votes on all matters brought before the holders of our common stock for approval and, therefore, represented a change of control.

	Effective January 2013 all common shares of the Company's common stock issued and outstanding were combined and reclassified on a one-for-one thousand basis. The effect of this reverse stock split has been retroactively applied to all periods presented.

	On February 2013, the Company, and its wholly-owned subsidiary, TriStar Consumer Products, Inc., a Nevada corporation (“TCP”), closed an Asset Purchase Agreement (the “Asset Purchase Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), and John Linderman and James Barickman, individuals (the “Shareholders”), under which the Company exercised its option to purchase the Beaute de Maman™ product line, in addition to the over-the-counter itch suppression formula (together, the “Business”). As consideration for the purchase of the Business the Company agreed to issue NCP, or its assignees, Seven Hundred Fifty Thousand (750,000) shares of its Series D Convertible Preferred Stock.

	On March 7, 2013, the Company entered into an Exclusive Manufacturing, Marketing and Distribution Definitive License Agreement (the “Agreement”) with Argentum Medical, LLC, a Delaware limited liability company (“Argentum”), under which the Company acquired an exclusive license to develop, market and sell products based on a technology called “Silverlon”, a proprietary silver coating technology providing superior performance related to OTC wound treatment. The license is for 15 years, with a possible 5 year extension. Under the Agreement, the Company is obligated to order a certain amount of proprietary Silverlon film each contract year and if the minimums are not met Argentum could cancel the Agreement. In exchange for these license rights the Company agreed to pay Argentum royalty payments based on the adjusted gross revenues generated by product sales, as well as issue Argentum a warrant to purchase up to 750,000 shares of its common stock with an exercise price of $0.50 per share.

	On May 6, 2013, the Company closed the acquisition of HemCon Medical Technologies Inc., an Oregon corporation (“HemCon”), pursuant to the terms of an Agreement for Purchase and Sale of Stock entered into by and between us and HemCon (the “Agreement”). The Agreement was entered into as part of HemCon’s Fifth Amended Plan of Reorganization in its bankruptcy proceeding (United States Bankruptcy Court, District of Oregon, Case No. 12-32652-elp11) and was approved by the Court as part of HemCon’s approved Plan of Reorganization. Under the Agreement, the Company purchased 100 shares of HemCon’s common stock, representing 100% of HemCon’s then-outstanding voting securities, in exchange for $3,139 in cash (the “Purchase Price”). The Purchase Price was paid to the Court and the Trustee of the bankruptcy proceeding to be distributed to HemCon’s creditors in accordance with the Plan of Reorganization.

	Prior to closing the acquisition of HemCon the Company borrowed money from several different parties, primarily the following:

	1)	A Promissory Note with DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $2,950. The note has an interest rate of 1.5% per month and is due on or before November 6, 2013. Additionally, a loan fee of 2% of the principal amount is due and payable by us to lender on or before the maturity date. In connection with this promissory note, we issued DayStar Funding, LP, warrants to purchase 1,770,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance.

	2)	A Promissory Note with the Lawrence K. Ingber Trust, dated June 14, 1980, as amended and restated March 6, 2006, in the principal amount of $100. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued the Lawrence K. Ingber Trust warrants to purchase 50,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance.

	3)	A Promissory Note with James Linderman, the father of one of our officers and directors, in the principal amount of $100. The note has an interest rate of 1.5% per month, simple interest, and is due on or before August 6, 2013. In connection with this promissory note, we issued Mr. James Linderman warrants to purchase 50,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance.

	4)	A Promissory Note with James Barickman, one of our officers and directors, in the principal amount of $50. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued Mr. James Barickman warrants to purchase 25,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance.

	5)	A Promissory Note with John Linderman, one of our officers and directors, in the principal amount of $50. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued Mr. John Linderman warrants to purchase 25,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance.

	6)	A Loan Agreement with an unaffiliated third party for $400 was paid in connection with the closing of the acquisition of HemCon. The loan has an interest rate of 10% per annum and is due on or before November 6, 2013 and was repaid in 2013.

	HemCon, founded in 2001, is a diversified life sciences company that develops, manufactures and markets innovative wound care/infection control medical devices. These products target the emergency medical, surgical, dental, military and over-the-counter (OTC), markets in the US and globally. HemCon’s advanced wound care and infection control products are designed to quickly stop moderate to severe hemorrhaging in OTC, surgery, trauma, battlefield injuries, and surgical wounds. The company’s wound care products are presently either chitosan-based or oxidized cellulose. Chitosan has long been recognized as a robust hemostat and provides natural antibacterial properties. Historically chitosan has been difficult to reliably incorporate into manufactured wound care products. HemCon has overcome these historical limitations and has been granted patents for its proprietary lyophilized and gauze-based manufacturing processes that allow for consistent and reliable commercial grade wound care and infection control products. HemCon’s original medical device product, the HemCon Bandage, was developed in partnership with the U.S. Army. Between 2003 and 2008, the bandage was the standard issue hemorrhage control bandage for all U.S. Army soldiers and is credited with saving hundreds of lives on the battlefield. Under the Reorganization Plan, HemCon kept its wound care/infection control medical devices business and all assets related thereto. The other segment of its operations, called the “LyP Product" which related to HemCon’s proprietary lyophilized human plasma and universal lyophilized plasma technology were spun out into a newly formed corporation and are not part of our acquisition of HemCon.

	As a result of the above transactions, the Company was involved in developing, manufacturing and marketing HemCon’s innovative wound care/infection control medical devices, as well as, developing, marketing and selling, NCP’s Beaute de Maman™ product line, which is a line of skincare and other products specifically targeted for pregnant women.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Note 2. Summary of Significant Accounting Policies	'
	Basis of Presentation and Principles of Consolidation

	The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries. All intercompany balances and transactions have been eliminated.

	Cash and Cash Equivalents

	Cash consists of funds deposited in checking accounts. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high quality of the institutions that have custody of the Company’s funds. The Company has not incurred any losses on such accounts.

	Accounts Receivable

	The Company extends credit to its customers in the normal course of business and performs ongoing credit evaluations of its customers. Accounts receivable are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer's current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of an allowance for doubtful accounts of $8 and $0, at December 31, 2013 and December 31, 2012, respectively.

	Use of Estimates

	In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments upon issuance, and estimating the useful lives of depreciable assets and whether impairment charges may apply.

	Revenue Recognition

	Product Sales Revenue

	The Company recognizes product sales revenue when there is persuasive evidence of an arrangement, prices are fixed and determinable, the product is shipped or delivered, title and risk of loss have passed to the customer, and collection is reasonably assured. Certain of its product sales are made to distributors. The Company's distributor arrangements do not provide distributors with product return rights or pricing adjustments. The Company recognizes product sales to distributors on a sell-in basis, when the product is delivered

	Deferred Revenue

	The Company defers nonrefundable up-front payments received from distributors. These fees are recognized on a straight-line basis over the contractual term of the related contract.

	Inventories

	Inventories are stated at the lower of standard cost (which approximates average cost) or market.

	Property and Equipment

	Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided using the straight-line method for financial reporting purposes based on the estimated useful lives of the various assets ranging from three to ten years. Maintenance and repair costs are charged to current earnings. Upon disposal of assets, the costs of assets and the related accumulated depreciation are removed from the accounts. Gains or losses are reflected in current earnings.

	Intangible assets

	Intangible assets consist of patents, customer lists, non-compete arrangements and a trade name. Patents, customer lists, non-compete arrangements and a trade name acquired in business combinations under the purchase method of accounting are recorded at fair value net of accumulated amortization since the acquisition date. Amortization is calculated using the straight line method over the estimated useful lives at the following annual rates:

		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16

	The Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined based on discounted cash flows.

	Other Receivables and Current Liabilities Related to Assets Sold

	Prior to the Company acquisition of HemCon, on February 6, 2013, HemCon concluded an asset sale with Bard Access Systems for its GuardIVa™ product plus associated intellectual property and trademark for $4,500 following on from a license and supply agreement in October 2012 for $500. GuardIVa™ has been classified as a discontinued operation in the Consolidated Statement of Operations. This sale and the proceeds which were realized facilitated the Company in emerging from Chapter 11 Bankruptcy. An amount of $1.5 million remains outstanding as deferred consideration which is payable on achieving certain regulatory requirements. This deferred consideration will be paid to the Secured Creditors under the bankruptcy case 12-32652-ELP11 pursuant to the HemCon Sale and purchase agreement on receipt of same. GuardIVa™ is a hydrophilic foam based IV site dressing for use at Catheter insertion sites. The dressing incorporates HemCon micro dispersed oxidized cellulose technology an active hemostatic ingredient along with CHG a generic antibacterial agent.

	Accumulated Other Comprehensive Income

	Comprehensive income is defined as the change in equity of a company during the period resulting from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. The primary difference between net income and comprehensive income for the Company results from foreign currency translation adjustments. Accumulated other comprehensive loss was $19 for the period ended December 31, 2013 and $0 at December 31, 2012. The financial position of foreign subsidiaries is translated using the exchange rates in effect at the end of the period, while income and expense items are translated at average rates of exchange during the period. The net losses resulting from foreign currency transactions are recorded in the consolidated statements of operations in the period incurred were $19 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.

	Concentration of Source of Materials

	The Company uses a raw material that must meet specific quality standards in its production process, which is currently purchased from one vendor. The Company mitigates the risk to its production process through purchasing quantities sufficient to meet its production needs in the near term and by having identified alternative sources of supply of an equivalent standard should they become necessary.

	Stock-Based Compensation

	Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit.

	Segment Reporting

The Company operates as one segment, in which management uses one measure of profitability. The Company is managed and operated as one business. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments. The Company generated $790 revenue from Europe and Asia and $2,986 from North America during 2013.

Accounting for Warrants

The Company accounts for the issuance of common stock purchase warrants issued in connection with equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

The Company assessed the classification of its common stock purchase warrants as of the date of each transaction and determined that such instruments met the criteria for equity classification. The warrants are reported on the consolidated balance sheet as a component of stockholders’ equity at fair value using the Black-Scholes valuation method.

Income Taxes

The Company adopted the provisions of ASC 740-10, which prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return.

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations.

Loss per Share

Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares (including redeemable shares) plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a significant effect to the accompanying consolidated financial statements.

Revenue Concentrations

The Company considers significant revenue concentrations to be counterparties who account for 10% or more of the total revenues generated by the Company during the period. For the year ended December 31, 2013, the amount of revenue derived from counterparties representing more than 10% of our total revenues was 13%. As of December 31, 2013 Two customers owed a total of 33% of accounts receivable.

Going_Concern_and_Managements_

Going Concern and Management's Plans	12 Months Ended
Going Concern and Management's Plans	Dec. 31, 2013
Notes to Financial Statements	'
Note 3. Going Concern and Management's Plans	'
	The Company's financial statements are prepared using accounting principles generally accepted in the United States of America (GAAP) applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. In addition, as of December 31, 2013, the Company had an accumulated deficit of $224,442, had incurred a net loss for the year ended December 31, 2012 of $12,647 and had negative working capital of $5,487. Funding has been provided by related parties as well as new investors committed to make it possible to maintain, expand, and ensure the advancement of the TriStar Wellness products. The Company anticipates that the same related parties may fund the Company on an as needed basis or will seek to obtain financing from other outside parties.

	The independent registered public accounting firm’s report on the financial statements for the fiscal year ended December 31, 2013 states that because the Company has suffered recurring operating losses from operations, there is substantial doubt about the Company’s ability to continue as a going concern. A “going concern” opinion indicates that the financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

	Strategy

	The Company intends to focus on purchasing or licensing rights to various health and wellness products using in-house expertise to develop, test, bring to market, and market a variety of health and wellness products. The Company is currently aggressively completing development of product lines that the Company believes address important market needs in target categories. The Company plans to primarily rely on internal R&D expertise complimented by an extensive network of product development specialists to optimize the product development and testing in advance of market launch. In all cases the Company’s plan is to own the unique formulas or processes via direct acquisition or license. As appropriate the Company will pursue and defend patents on each product offering to help protect from competitive incursion.

Business_Combinations

Business Combinations	12 Months Ended
Business Combinations	Dec. 31, 2013
Notes to Financial Statements	'
Note 4. Business Combinations	'
	NorthStar Consumer Products, LLC

	In February, 2013, the Company closed an Asset Purchase Agreement (the “Asset Purchase Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), and John Linderman and James Barickman, individuals (the “Shareholders”), under which the Company exercised an option to purchase a brand of skincare and other products specifically targeted for pregnant women (the Beaute de Maman product line), in addition to an over-the-counter itch suppression formula (together, the “Business”). Previously, the Company entered into to that certain License and Asset Purchase Option Agreement dated June 25, 2012 with NCP (the “License Agreement”), under with the Company licensed the Business from NCP and had the option to purchase the Business from NCP upon certain conditions being satisfied. As set forth in the Asset Purchase Agreement those conditions were either satisfied or renegotiated to the satisfaction of the parties and the Company exercised an option, and purchased, the Business from NCP. As consideration for the purchase of the Business the Company agreed to issue NCP, or its assignees, Seven Hundred Fifty Thousand (750,000) shares of Series D Convertible Preferred Stock. The fair value of the consideration given was $2,813 and the value of the assets received was $15, liability was $7 and such fair value of assets was impaired during 2013. There was no acquired assets other than intangible assets and therefore no purchase price is being presented. The fair values for acquired intangible assets of NCP were determined by the Company using a valuation performed by an independent valuation specialist. In addition, the Company also recorded an additional $2,805 expense based on the valuation of the Series D Convertible Preferred Stock determined by a valuation specialist. This transaction was recorded as a component of research and development expenses during 2013 because the viability of an alternative future use was uncertain.

	HemCon

	On May 6, 2013, the Company closed the acquisition of HemCon, an Oregon corporation (“HemCon”), pursuant to the terms of an Agreement for Purchase and Sale of Stock entered into by and between us and HemCon (the “Agreement”). The Agreement was entered into as part of HemCon’s Fifth Amended Plan of Reorganization in its bankruptcy proceeding (United States Bankruptcy Court, District of Oregon, Case No. 12-32652-elp11) and was approved by the Court as part of HemCon’s approved Plan of Reorganization. Under the Agreement, the Company purchased 100 shares of HemCon’s common stock, representing 100% of HemCon’s then-outstanding voting securities, in exchange for approximately $3.1 million (the “Purchase Price”). The Purchase Price was paid to the Court and the Trustee of the bankruptcy proceeding to be distributed to HemCon’s creditors in accordance with the Plan of Reorganization.

	The acquisition has been accounted for under the acquisition method of accounting. Accordingly, the assets and liabilities of the acquired entity were recorded at their estimated fair values at the date of the acquisition. The operating results for HemCon have been included in the Company's consolidated financial statements since the acquisition date.

	The purchase price allocation is based on estimates of fair value as follows (in thousands):

	Accounts receivables	$	653
	Other receivables		1,500
	Inventory		1,410
	Other current assets		23
	Prepaid expenses		156
	Fixed assets		1,193
	Accounts payable and accrued expenses		(341	)
	Current liabilities related to assets held for sale		(1,500	)
	Deferred revenue		(882	)
	Patents		336
	Customer list		198
	Trade name		266
	Non-compete agreement		127
	Total acquisition cost allocated	$	3,139

	Management assigned fair values to the identifiable intangible assets through a combination of the relief from royalty method and the multi-period excess earnings method.

	The useful lives of the acquired intangibles are as follows:

		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16

	During year ended December 31, 2013, the Company incurred $100 of acquisition costs, all of which were expensed in operations during the second quarter of 2013.

	The following unaudited pro forma financial information presents results as if the acquisition of HemCon had occurred on January 1, 2013 and January 1, 2012 (in thousands):

	Year Ended December 31 ,
	(Unaudited)	2013			2012

	Total revenue	$	5,469			$	4,943
	Net loss	$	(13,336	)		$	(9,751	)

	For purposes of the pro forma disclosures above, the primary adjustments for the year ended December 31, 2013 and December 31, 2012 include the elimination of acquisition-related charges of $100 and additional interest expense.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2013
Notes to Financial Statements	'
Note 5. Inventories	'
	Inventories, net consist of the following at December 31, 2013 and December 31, 2012 (in thousands):

		December 31,
		2013		2012
	Raw materials	$	318	$	-
	Work in Progress		251		-
	Finished Goods		575		12
		$	1,144	$	12

	Reserve for obsolescence was approximately $251 for year ended December 31, 2013 and $0 for December 31, 2012.

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2013
Notes to Financial Statements	'
Note 6. Property and Equipment	'
	Property and equipment consist of the following at December 31, 2013 and December 31, 2012 (in thousands):

		Estimates Useful Life	December 31,
		(Years)	2013			2012
	Manufacturing Equipment	10-Jul	$	623		$	-
	Leasehold Improvements	7	$	520			-
	Office Furniture and Equipment	7-Mar	$	32			-
	Computer Equipment and Software	5-Jan	$	12			1
	Construction in Progress			6			-
				1,193			1
	Less: Accumulated Depreciation, amortization and impairments			(196	)		-
			$	997		$	1

	Depreciation expense was approximately $196 for the year ended December 31, 2013, respectively and $0 for the year ended December 31, 2012, respectively.

Loans_Payable

Loans Payable	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Note 7. Loans Payable	'
		December 31,		December 31,
		2013		2012
	Short-term notes (net of debt discount $497 and $0 as December 31, 2013 and December 31, 2012, respectively)	$	714	$	50
	Short-term notes - related party		3,970		525
		$	4,684	$	575

		December 31,		December 31,
		2013		2012
	Convertible notes	$	356		-
			356	$	-

	Promissory Notes

	2012 Activity

	During July 2012, The Company retained short term loans on demand of $400 to a related party (Sue Alter) as a result of the sale of the Company’s BPAC Subsidiaries. The note was modified in July 2012 to include a beneficial conversion feature. The conversion price of the modified note is $0.008 per share.

	During the fourth quarter of 2012, the Company issued convertible demand notes to a related party for $125 which is convertible into 33,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 33,333 shares of Series D Convertible Preferred Stock.

	During the fourth quarter of 2012, the Company issued convertible demand notes to a third party for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

	2013 Activity

	During the first quarter of 2013, the Company issued convertible demand notes to a related party for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

	During the first quarter of 2013, Sue Alter, a related party, sold her convertible notes with accrued interest with a principal balance of $400 to three separate non-related parties. Subsequent to this sale, the new holders partially converted their notes payable, in accordance with the original terms of the notes, with a principal amount of $32 into 4,029,200 common shares.

	During the second quarter of 2013, a third party partially converted their notes payable, in accordance with the original terms of the notes, with a principal amount of $8 into 1,000,000 common shares.

	During the second quarter of 2013, the Company issued promissory notes to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $2,950. The note has an interest rate of 1.5% per month and is due on or before November 6, 2013. In connection with this promissory note, we issued DayStar Funding, LP, warrants to purchase 1,770,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

	During the second quarter of 2013, the Company issued a promissory note with Mr. Frederick A. Voight, the chief investment officer and director, in the principal amount of $15. The note has an interest rate of 1.5% per month, simple interest, and is due on or before August 6, 2013. In connection with this promissory note, we issued Mr. Frederick A. Voight warrants to purchase 9,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. The warrants were valued at approximately $1.77 per warrant using the Black-Scholes model. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.04%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. This note is currently past due.

	During the second quarter of 2013, the Company issued a promissory note with James Linderman, the father of one of our officers and directors, in the principal amount of $100. The note has an interest rate of 1.5% per month, simple interest, and is due on or before August 6, 2013. In connection with this promissory note, we issued Mr. James Linderman warrants to purchase 50,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. The warrants were valued at approximately $1.77 per warrant using the Black-Scholes model. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.04%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. This note is currently past due.

	During the second quarter of 2013, the Company issued a promissory note with James Barickman, one of our officers and directors, in the principal amount of $50. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued Mr. James Barickman warrants to purchase 25,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. The warrants were valued at approximately $1.77 per warrant using the Black-Scholes model. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.04%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. This note is currently past due.

	During the second quarter of 2013, the Company issued a promissory note with John Linderman, one of our officers and directors, in the principal amount of $50. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued Mr. John Linderman warrants to purchase 25,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. The warrants were valued at approximately $1.77 per warrant using the Black-Scholes model. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.04%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. This note is currently past due.

	During the second quarter of 2013, the Company issued a promissory note with Lawrence Ingber, an unaffiliated third party, in the principal amount of $100. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, the Company issued to the holder warrants to purchase 50,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. The warrants were valued at approximately $1.77 per warrant using the Black-Scholes model. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.04%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. This note is currently past due.

	During the second quarter of 2013, the Company issued a promissory note with Harry Pond in the principal amount of $36. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, the Company issued to the holder warrants to purchase 21,600 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. The warrants were valued at approximately $1.77 per warrant using the Black-Scholes model. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.04%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. This note is currently past due.

	During the second quarter of 2013, the Company entered into a Loan Agreement with Combat Medical Systems, an unaffiliated third party for a loan of up to $400, payable in two tranches, $400 was paid in connection with the closing of the acquisition of HemCon, and $350 payable in the future subject to contingencies. The loan has an interest rate of 10% per annum and is due on or before November 6, 2013. The note was repaid in full on November 26, 2013.

	During the second quarter of 2013, the Company recorded 2% loan fees in aggregate for approximately $60 in connection with the promissory notes issued in May 2013. In connection with note issuances during the second quarter of 2013, the Company recorded a $1,726 discount at issuance and recorded debt discount amortization of $1,726 during the year ended December 31, 2013. Of the $1,726 discount recorded at issuance the portion relating to the detachable warrants of $1,666 was credited to additional paid in capital and the $60 loan fee described above was credited to the loan principal.

	During the third quarter of 2013, the Company issued a promissory note with John Linderman, one of our officers and directors, in the principal amount of $175. The note has an interest rate of 22% per annum, simple interest, and is due on or before October 18, 2013. No warrants were issued in connection with the promissory note. This note was repaid in full during the fourth quarter of 2013.

	During the third quarter of 2013, the Company issued promissory notes to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $470. The note has an interest rate of 1.5% per month and is due on or before November 6, 2013. In connection with this promissory note, we issued DayStar Funding, LP, warrants to purchase 282,000 shares of our common stock at an exercise price $2.69 per share, which was the fair market value of our common stock on the date of issuance. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.96% to 1.35%, volatility – 78.06% to 80.75%, expected term – 4 years, expected dividends– N/A.

	During the third quarter of 2013, the Company recorded 2% loan fees in aggregate for approximately of $10 in connection with the promissory notes issued in August 2013. In connection with note issuances during the third quarter of 2013, the Company recorded a $220 discount at issuance and recorded debt discount amortization of $220 for the year ended December 31, 2013. Of the $220 discount recorded at the issuance the portion relating to the detachable warrants of $210 was credited to additional paid in capital and the $10 loan fee described above was credited to the loan principal.

	During the fourth quarter of 2013, a third party partially converted their notes payable, in accordance with the original terms of the notes, with a principal amount of $4 into 500,000 common shares.

	During the fourth quarter of 2013, the Company paid the second payment against the Loan Agreement with Combat Medical System in the amount of $400, in connection with the closing of the acquisition of HemCon.

	During the fourth quarter of 2013 the Company issued promissory notes to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $300. The note has an interest rate of 18% per annum, simple interest and is due on or before May 1, 2014. No warrants were issued in connection with the promissory note. The Company repaid $70 of this promissory note during 2013.

	During the fourth quarter of 2013 the Company issued a promissory note to a third party, in the principal amount of $1,100. The note has an interest rate of 21% per annum, simple interest and is due on or before November 30, 2014. In connection with this promissory note, the Company issued warrants to purchase 1,000,000 shares of our common stock at an exercise price $1.80 per share, which was the fair market value of our common stock on the date of issuance. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.39%, volatility – 85.8%, expected term – 4 years, expected dividends– N/A. The debt discount related to the warrants are being amortized over a one year period (through maturity) on a straight-line basis. The Company recorded a debt discount related to the warrants of $556 by crediting additional paid in capital. Amortization expense on the debt discount was $56 for the year ended December 31, 2013.

	The Company recorded imputed interest on convertible debentures and interest expense of $31 and $34 for year ended December 31, 2013 and 2012 respectively, based upon a market interest rate of 8% and accrued interest based on the stated rate of 0.5%.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Note 8. Stockholders' Equity	'
	Series A, B and C Convertible Preferred Stock – Change of Control Transaction

	On April 27, 2012, the Company was party to an agreement whereby Rockland Group, LLC, a Texas limited liability company (“Rockland”), purchased six hundred and twenty thousand (620,000) shares of Biopack Environmental Solutions, Inc. Series A Convertible Preferred Stock (“Series A Preferred Shares”), one million (1,000,000) shares of Biopack Environmental Solutions, Inc. Series B Convertible Preferred Stock (“Series B Preferred Shares”) and seven hundred ten thousand (710,000) shares of Biopack Environmental Solutions, Inc. Series C Convertible Preferred Stock (“Series C Preferred Shares”) from the holders of those shares. The Series A Preferred Shares and Series B Preferred Shares were issued prior to December 31, 2011. The Series C Preferred Shares were issued in April 2012. Together the Shares represented approximately 63% of our outstanding votes on all matters brought before the holders of our common stock for approval and, therefore, represented a change of control. Each share of Series A, B and C Convertible Preferred Stock is convertible into 5 shares of common stock on the date of this transaction.

	Intangible Asset and Inventory Acquisition in Exchange for Series D Convertible Preferred Stock

	On June 25, 2012, the Company entered into a License and Asset Purchase Option Agreement (the “Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), under which TriStar Consumer Products, Inc., acquired the exclusive license to develop, market and sell, NCP’s Beaute de Maman product line, which is a line of skincare and other products specifically targeted for pregnant women. In addition, the Company acquired the exclusive license rights to develop, market and sell NCP’s formula being developed for itch suppression, which would be sold as an over-the-counter product, if successful. These licenses are for a period of up to one year, subject to earlier termination upon specified events. During the term of the license, the assets and being licensed will be run by management of NCP pursuant to a consulting agreement. As a result of these license rights the Company are now responsible for developing, marketing and selling the “Beaute de Maman” products, as well as NCP’s anti-itch formula, including all expenses, contractual arrangements, etc., related to product development, manufacturing, marketing, selling, bottling and packaging, and shipping. The Company will also receive all proceeds derived from sales of the products, other than the amounts owed to Dr. Michelle Brown, from whom NCP purchased the “Beaute de Maman” assets. Such proceeds were recorded as a reduction of general and administrative expenses. Under the arrangement with Dr. Brown she is entitled to approximately seven percent (7%) of net revenue for all products sold under the Beaute de Maman brand name and derived from formulas transferred under the agreement with NCP for a 20 year period ending December 31, 2031. In exchange for these license rights the Company agreed to issue NCP 225,000 shares of our Series D Convertible Preferred Stock. This transaction closed on June 26, 2012. Additionally, under the Agreement, in connection with the Company’s license rights and to ensure it can fulfill any immediate orders timely, the Company purchased all existing finished product of the Beaute de Maman product line currently owned by NCP. In exchange for the inventory the Company agreed to issue NCP 25,000 shares of Series D Convertible Preferred Stock. Each share is convertible into twenty five shares of common stock. The fair value of the shares amounted to $89 and was based on the closing common stock price of common stock and the conversion ratio (each share of Series D Convertible Preferred Stock is convertible into 25 shares of common stock) on the date of this transaction. The Company recorded $84 as an intangible asset and $5 as inventory on the date of the transaction.

	Issuance of Series D Convertible Preferred Stock for Cash and Services

	On June 29, 2012, the Company entered into a Stock Purchase Agreement with Rockland Group, LLC, an entity owned and controlled by Harry Pond, one the Company’s officers and directors (the “Stock Purchase Agreement”). Under the Stock Purchase Agreement, Rockland Group agreed to purchase 1,540,000 shares of our Series D Convertible Preferred Stock. The value of the shares was based upon the cash received and expenses contributed.

	The Company issued 1,046,760 shares of Series D Convertible Preferred Stock in exchange for $209,352 in cash. In addition, the Company issued 493,240 shares of Series D Convertible Preferred Stock in exchange for $354,983 of expenses contributed by Rockland on behalf of the Company (total Series D Preferred shares issued is 1,540,000). The value of the expenses contributed was based on the closing common stock price of common stock and the conversion ratio (each share of Series D Convertible Preferred Stock is convertible into 25 shares of common stock) the date of this transaction.

	Issuance of Series D Convertible Preferred Stock for Research and Development

	On July 11, 2012, the Company, entered into a Purchase and Assignment of Rights Agreement (the “Agreement”) with RWIP, LLC, an Oregon limited liability company (“RWIP”), under which the Company was assigned rights to receive certain royalty payments under previously executed agreements between RWIP and a third party. The royalty payments are equal to Twenty Percent (20%) of all net income (revenue minus expenses) received by the third party InterCore Energy, Inc., a Delaware corporation (fka. I-Web Media, Inc.) (“ICE”) from certain assets owned by ICE, as set forth in that certain asset purchase agreement between RWIP and ICE dated December 10, 2010. In exchange for these rights we agreed to issue RWIP Two Million (2,000,000) shares of our Series D Convertible Preferred Stock. The transaction closed on July 11, 2012. The fair value of the shares amounted to $700,001 and was based on the closing common stock price of common stock and the conversion ratio (each share of Series D Convertible Preferred Stock is convertible into 25 shares of common stock) on the date of this transaction. This transaction was recorded as a component of research and development expenses during 2012 because the viability of an alternative future use was uncertain.

	Recapitalization of Assets and Liabilities

	On July 11, 2012, the Company exercised its rights under the Subsidiary Option Agreement by sending a signed Notice of Exercise to the Escrow Agent, pursuant to the terms of the Subsidiary Acquisition Agreement. The Company also sent a copy of the Notice of Exercise directly to the Purchaser as well. As a result of the Company exercising its rights under the Subsidiary Option Agreement, the Company no longer owned the Subsidiary Shares or the Subsidiaries, including any of their assets or liabilities. The Company recorded this transaction as a recapitalization and according recorded such assets and liabilities as well accumulated other comprehensive income as a $1,894,877 adjustment to additional paid in capital due to the related party nature of the spin off.

	Acquisition of Beute de Maman product Line from NorthStar Consumer Products, LLC

	In February, 2013, the Company closed an Asset Purchase Agreement (the “Asset Purchase Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), and John Linderman and James Barickman, individuals (the “Shareholders”), under which the Company exercised an option to purchase a brand of skincare and other products specifically targeted for pregnant women (the Beaute de Maman product line), in addition to an over-the-counter itch suppression formula (together, the “Business”). Previously, the Company entered into to that certain License and Asset Purchase Option Agreement dated June 25, 2012 with NCP (the “License Agreement”), under with the Company licensed the Business from NCP and had the option to purchase the Business from NCP upon certain conditions being satisfied. As set forth in the Asset Purchase Agreement those conditions were either satisfied or renegotiated to the satisfaction of the parties and the Company exercised an option, and purchased, the Business from NCP. As consideration for the purchase of the Business the Company agreed to issue NCP, or its assignees, Seven Hundred Fifty Thousand (750,000) shares of Series D Convertible Preferred Stock. The fair value of the consideration given was $2,813 and assets received was $15 liabilities assumed $7 and such fair value was immediately impaired, due to the uncertainty of future cash flows during 2013. There was no acquired assets other than intangible assets and therefore no purchase price is being presented. The fair values for acquired intangible assets of NCP were determined by the Company using a valuation performed by an independent valuation specialist. In addition, the Company also recorded an additional $2,805 expense based on the stock valuation on the date of this transaction. This transaction was recorded as a component of research and development expenses during 2013 because the viability of an alternative future use was uncertain.

	Forgiveness of Accounts Payable

	During the 4th quarter of 2013, NCP forgave certain accrued expenses incurred by the Company and due to NCP. Due to the related party nature of this transaction, The Company recorded a $78 charge to additional paid in capital.

	Diluted Shares

	Each share of Preferred A, B and C is convertible into five shares of common stock (pre-split and post-split basis). Each share of Preferred D is convertible into twenty five shares of common stock (pre-split and post-split basis). Convertible preferred stock was considered anti-dilutive for the twelve months ended December 31, 2012, due to net losses. As of December 31, 2012, there are 3,790,000 Series D Convertible Preferred Shares which are convertible into 94,750,000 of common shares. All Series D Convertible Preferred Stock voting rights are on an “as converted to common stock” basis. Dividend are not mandatory. If declared by the Board Series D Preferred Stock shall have preference over common stock and equal to other series of preferred stock. As of December 31, 2012, there are 2,330,000 Series A, B and C Convertible Preferred Shares which are convertible into 11,650,000 of common shares.

	There were 405,000 shares of Series A, 1,000,000 shares of Series B and no shares of Series C outstanding as of December 31, 2013. Each share of Preferred D is convertible into twenty five shares of common stock. Convertible preferred stock was considered anti-dilutive for the year ended December 31, 2013 and 2012, due to net losses. As of December 31, 2013, there are 4,216,667 Series D Convertible Preferred Shares which are convertible into 105,416,675 of common shares. All Series D Convertible Preferred Stock voting rights are on an “as converted to common stock” basis. Dividends are not mandatory. If declared by the Board Series D Preferred Stock shall have preference over common stock and equal to other series of preferred stock. As of December 31, 2013, there are 5,782,600 warrants which are convertible into one share of common stock. There were no warrants outstanding as of December 31, 2012.

	The Company has determined that common stock equivalents in excess of available authorized common shares are not derivative instruments due to the fact that an increase in authorized shares is within the Company’s control.

	Note Conversions

	All note conversions were within the original conversion terms and therefore no gain or loss was recorded on these conversions.

	During the fourth quarter of 2012, the Company issued convertible demand notes to a related party for $125 which is convertible into 33,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 33,333 shares of Series D Convertible Preferred Stock.

	During the fourth quarter of 2012, the Company issued convertible demand notes to a third party for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

	During the first quarter of 2013, the Company issued convertible demand notes to a related party for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

	In January 2013, the Company received a notice of conversion from Sue E. Alter, notifying the Company that she wished to convert $0.0336 of principal and interest due under that certain TriStar Wellness Solutions, Inc. Convertible Promissory Note dated April 27, 2012 into 4,200 shares of our common stock. The shares were issued to Ms. Alter, without a restrictive legend.

	In January 2013, the Company received a notice of conversion from a noteholder, notifying the Company that he wished to convert $0.0336 of principal and interest due under that certain TriStar Wellness Solutions, Inc. Convertible Promissory Note dated January 28, 2013 into 4,200 shares of common stock. The shares were issued to Mr. Kent C Chisman on or about January 31, 2013, without a restrictive legend.

	In February 2013, the Company received a notice of conversion from a noteholder, notifying the Company that he wished to convert $0.1664 of principal and interest due under that certain TriStar Wellness Solutions, Inc. Convertible Promissory Note dated January 28, 2013 into 20,800 shares of common stock. The shares were issued to Mr. Kent C Chisman on or about February 14, 2013, without a restrictive legend.

	In February 2013, the Company received a notice of conversion from a noteholder, notifying the Company that they wished to convert $32 of principal and interest due under that certain TriStar Wellness Solutions, Inc. Convertible Promissory Note dated February 21, 2013 into 4,000,000 shares of common stock. The shares were issued to a third party on or about March 4, 2013, without a restrictive legend.

	During the second quarter of 2013, a third party partially converted their notes payable, in accordance with the original terms of the notes, with a principal amount of $8 into 1,000,000 common shares.

	During the fourth quarter of 2013, a third party partially converted their notes payable, in accordance with the original terms of the notes, with a principal amount of $4 into 500,000 common shares.

	Share Conversions

	On February 5, 2013, the Company received notices of conversion from several of its largest shareholders and related-parties:

·	Rockland Group, LLC, an entity controlled by Mr. Harry Pond, one of the Company's former officers and former sole director, converted both 215,000 shares of Series A Convertible Preferred Stock into 1,075,000 shares of common stock and 710,000 shares of Series C Convertible Preferred Stock into 3,550,000 shares of our common stock. These shares were issued to Rockland Group, LLC, with a restrictive legend.

·	Rivercoach Partners, LP, an entity controlled by Mr. Frederick A. Voight, converted 400,000 shares of Series D Preferred Stock into 10,000,000 shares of common stock. These shares were issued to Rivercoach Partner, LP, with a restrictive legend.

·	Highpeak, LLC, an entity controlled by Mr. Michael S. Wax, converted 780,000 shares of Series D Preferred Stock into 19,500,000 shares of our common stock. These shares were issued to Highpeak, LLC, with a restrictive legend.

·	NorthStar Consumer Products, LLC, an entity controlled by Mr. John Linderman and Mr. Jamie Barickman converted 250,000 shares of Series D Preferred Stock into 6,250,000 shares of our common stock. These shares were issued to NorthStar Consumer Products, LLC, with a restrictive legend.

In July 2013, the Company received a notice of Irrevocable Stock Power from NorthStar Consumer Products, LLC, one of the largest shareholders and an entity controlled by Mr. John Linderman and Mr. Jamie Barickman, notifying the Company that NorthStar Consumer Products, LLC wished to cancel 2,500,000 shares of Common Stock in exchange for 100,000 shares of our Series D Convertible Preferred Stock. The value of the preferred shares issued was equal to the value of the common shares cancelled therefore no loss was recorded for this transaction.

In July 2013, the Company received a notice of Irrevocable Stock from M&K Family Limited Partnership, one of the largest shareholders, notifying the Company that M&K Family Limited Partnership wished to cancel 15,750,000 shares of Common Stock in exchange for 630,000 shares of our Series D Convertible Preferred Stock. The value of the preferred shares issued was equal to the value of the common shares cancelled therefore no loss was recorded for this transaction.

In July 2013, the Company received a notice of Irrevocable Stock Power from Rivercoach Partners, LP, one of the largest shareholders and an entity controlled by Mr. Frederick A. Voight, notifying the Company that Rivercoach Partners, LP wished to cancel 6,250,000 shares of Common Stock in exchange for 250,000 shares of our Series D Convertible Preferred Stock. The value of the preferred shares issued was equal to the value of the common shares cancelled therefore no loss was recorded for this transaction.

Share Issuances for Cash

In February 2013 the Company issued 26,667 shares of Series D Convertible Preferred Stock to Rockland Group, LLC in exchange for $100 in cash.

In March 2013 the Company issued 40,000 shares of Series D Convertible Preferred Stock to two third parties in exchange for $150 in cash.

During the second quarter of 2013, the Company issued for cash, 295,000 shares of common stock for approximately $227 in cash.

During the third quarter of 2013, the Company issued for cash, 100,000 shares of common stock for $100 in cash.

During the fourth quarter of 2013, the Company issued for cash, 194,445 shares of common stock for approximately $175 in cash. The shares were issued to John Linderman.

Detachable Warrants

During the second quarter of 2013, the Company issued Promissory Notes containing 1,950,600 detachable Warrants. The detachable Warrants were valued at approximately $1.77 per warrant using the Black-Scholes model at June 30, 2013. The relative fair value of the detachable Warrants compared to the debt of approximately $1,651 was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.48% - 0.77%, volatility – 92.45%, expected term – 4 years, expected dividends– N/A. The debt discount related to the warrants are being amortized over a nine month period (through maturity) on a straight-line basis.

During the third quarter of 2013, the Company issued Promissory Notes containing 282,000 detachable Warrants. The detachable Warrants were valued at approximately $1.19 per warrant using the Black-Scholes model at September 30, 2013. The relative fair value of the detachable Warrants compared to the debt of approximately $183 was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 0.96% to 1.35%, volatility – 78.06% to 80.75%, expected term – 4 years, expected dividends– N/A. The debt discount related to the warrants are being amortized over a nine month period (through maturity) on a straight-line basis.

During the fourth quarter of 2013, the Company issued Promissory Notes containing 1,000,000 detachable Warrants. The detachable Warrants were valued at approximately $1.19 per warrant using the Black-Scholes model at December 31, 2013. The relative fair value of the detachable Warrants compared to the debt of approximately $556 was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of December 31, 2013. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.39%, volatility – 85.8%, expected term – 4 years, expected dividends– N/A. The debt discount related to the warrants are being amortized over a one year period (through maturity) on a straight-line basis.

Warrants for Services

During the first quarter of 2013, the Company issued 350,000 fully vested warrants to consultants with exercise prices of $0.45 and with a five year terms. Each warrant is exercisable into one share of common stock. The fully vested warrants were valued at the closing price of the Company’s common stock on the date issued and amounted to approximately $688. The fair value of the 375,000 warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions: approximate risk free interest rate - 0.86%, volatility - 85%, expected term - 4 years, expected dividend - N/A.

During the first quarter of 2013, the Company issued 25,000 warrants to Chord Advisors, LLC with an exercise price of $0.45 and a five year term. Each warrant is exercisable into one share of common stock. The warrants were valued at the closing price of the Company’s common stock on the date granted and amounted to $19,648. The fair value of the 25,000 warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions: risk free interest rate - 0.85%, volatility - 85%, expected term - 4 years, expected dividend n/a.

During the fourth quarter of 2013, the Company converted approximately $1.1 million in Executive Officers compensation into 2,200,000 options with a fair value of $1.9 million, with a strike price of $1.00 per share. The Company recorded a loss on inducement expense of $0.8 million relating to the salary conversion. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.75%, volatility – 85.5%, expected term – 2.5 years, expected dividends– N/A.

Warrants for Research and Development

In February 2013, the Company entered into an Asset Purchase Agreement (the “HLBCDC Asset Purchase Agreement”) with HLBC Distribution Company, Inc. (“HLBCDC”), under which the Company exercised an option to purchase the Soft & Smooth Assets held by HLBCDC. The Soft & Smooth Assets include all rights, interests and legal claims to that certain inventions entitled “Delivery Devise with Invertible Diaphragm” as further defined in the Marketing Agreement (the “Soft and Smooth Assets”). Previously, we entered into a Marketing and Development Services Agreement (the “Marketing Agreement”) with InterCore Energy, Inc., a Delaware corporation (“ICOR”), under which the Company was retained to market and develop the Soft and Smooth Assets and were granted the exclusive option, in the Company’s sole discretion, to purchase the Soft & Smooth Assets from ICOR. Subsequently, ICOR sold the Soft and Smooth Assets to HLBCDC, transferring the rights to purchase the Soft and Smooth Assets from ICOR to HLBCDC. In exchange for the Soft and Smooth Assets the Company agreed to issue to HLBCDC warrants enabling HLBCDC to purchase One Hundred Fifty Thousand (150,000) shares of common stock at One Dollar ($1) per share, with a four (4) year expiration period. The warrants were valued at the closing price of the Company’s common stock on the date granted and amounted to approximately $100. The fair value of the 150,000 warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions: risk free interest rate - 0.88%, volatility - 85%, expected term – 4 years, expected dividend – N/A. The warrants were expensed due to the uncertainty of the level of future cash flows.

On March 7, 2013, the Company entered into an Exclusive Manufacturing, Marketing and Distribution Definitive License Agreement (the “Agreement”) with Argentum Medical, LLC, a Delaware limited liability company (“Argentum”), under which the Company acquired an exclusive license to develop, market and sell products based on a technology called “Silverlon”, a proprietary silver coating technology providing superior performance related to OTC wound treatment. The license is for 15 years, with a possible 5 year extension. Under the Agreement, the Company is obligated to order a certain amount of proprietary Silverlon film each contract year and if the minimums are not met Argentum could cancel the Agreement. In exchange for these license rights the Company agreed to pay Argentum royalty payments based on the adjusted gross revenues generated by product sales, as well as issue Argentum a warrant to purchase up to 750,000 shares of our common stock with an exercise price of $0.50 per share. The warrant vests in two equal installments of 375,000 shares each, with the vesting based on product’s success in obtaining certain approvals from the Food and Drug Administration. The Company recorded 375,000 non-contingent warrants during the first quarter of 2013 with a fair value of approximately $821. The fair value was determined using the Black-Scholes Option Pricing Model with the following assumptions: risk free interest rate - 0.85%, volatility - 85%, expected term - 4 years, expected dividend n/a. The warrants were expensed due to the uncertainty of the level of future cash flows. The remaining 375,000 warrants are unvested due to the underlying contingency being unresolved.

Deferred_Income_Taxes

Deferred Income Taxes	12 Months Ended
Deferred Income Taxes	Dec. 31, 2013
Notes to Financial Statements	'
Note 9. Deferred Income Taxes	'
	The Company uses the asset and liability approach to account for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.

	On January 1, 2007, the Company adopted an accounting standard which clarifies the accounting for uncertainty in income taxes recognized in financial statements. This standard provides guidance on recognizing, measuring, presenting and disclosing in the financial statements uncertain tax positions that a company has taken or expects to take on a tax return.

	During both 2013 and 2012, the Company incurred a net loss and therefore had no tax liability. The Company does not have any material uncertain income tax positions. As a result of significant losses and uncertainty of future profit, the net deferred tax asset generated by the loss carry forward has been fully reserved. The cumulative net operating loss carry forward is approximately $5,601 and $730 at December 31, 2013 and 2012, respectively, and will expire in the year ended 2033. All tax losses prior to the year ended December 31, 2012 have been eliminated due to the change in control during the year ended December 31, 2012.

	The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2013 and 2012 are comprised of the following:

		As of			As of
		December 31,			December 31,
		2013			2012
	Deferred tax asset
	Net operating loss carryovers	$	2,184		$	255
	Intangible asset amortization		29			-
	Stock-based compensation		1,721			-
	Amortization of debt discount		949			-
	Inducement expenses		313			-
	Total deferred tax assets		5,196			255
	Valuation Allowance		(5,196	)		(255	)
	Deferred tax asset, net of allowance	$	-		$	-

	The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:

		For year ended			For year ended
		December 31,			December 31,
		2013			2012
	Statutory federal income tax rate		-34	%		-34	%
	State taxes, net of federal tax benefit		-5	%		0	%
	Meals & entertainment		0	%		0	%
	Imputed interest		0.1	%		0	%
	Valuation Allowance		38.9	%		34	%
	Income tax provision (benefit)		0	%		0	%

		For year ended			For year ended
		December 31,			December 31,
		2013			2012
	Federal
	Current	$	-		$	-
	Deferred		(4,530	)		255
	State
	Current		-			-
	Deferred		(666	)		-
	Change in valuation allowance		5,143			(255	)
	Income tax provision (benefit)	$	-		$	-

Discontinued_Operation

Discontinued Operation	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Note 10. Discontinued Operation	'
	On November 3, 2011, the People’s Court of Guandong Jiangmen Pengjiang District held a hearing relating to the Company’s landlord’s claim for unpaid rent for its factory plus penalty interest and other claims. The landlord had made a claim for payment of overdue rent in the amount of RMB 1,236, penalty interest in the amount of RMB 1,068 and a claim for potential loss of income in the amount of RMB 618, for a total amount claimed of RMB 2,922 (approximately $451). At the hearing, the Court ruled that after two unsuccessful attempts to auction the factory’s assets at the minimum level set by the Court appointed independent valuation company’s fair market assessment price, the Court set the reference value at RMB 3,613 (approximately $569) and transferred all the assets to the landlord. The landlord is legally responsible for settling any claims made by creditors, and the case has been closed.

	On April 27, 2012, the Company entered into a Subsidiary Acquisition Option Agreement (“Subsidiary Option Agreement”) with Xinghui Ltd., a Chinese entity (“Purchaser“), under which the Company may, in our sole discretion, sell the Subsidiary Shares to Purchaser. The “Subsidiary Shares” consists of 100% ownership of the following wholly-owned subsidiaries: Roots Biopack (Intellectual Property) Limited, incorporated in Hong Kong, Roots Biopark Limited, incorporated in Hong Kong, Jiangmen Roots Biopack Ltd., incorporated in the People’s Republic of China, Starmetro Group Limited, incorporated in the British Virgin Islands and Biopack Environmental Limited (fka E-ware Corporation Limited), incorporated in Hong Kong (together the “BPAC Subsidiaries”).

	On July 11, 2012, the Company exercised its rights under the Subsidiary Option Agreement by sending a signed Notice of Exercise to the Escrow Agent, pursuant to the terms of the Subsidiary Acquisition Agreement. The Company also sent a copy of the Notice of Exercise directly to the Purchaser as well. As a result of the Company exercising its rights under the Subsidiary Option Agreement, the Company no longer owned the Subsidiary Shares or the BPAC Subsidiaries, including any of their assets or liabilities. The Company recorded this transaction as a recapitalization and according recorded such assets and liabilities as well accumulated other comprehensive income as a $1,899 adjustment to additional paid in capital.

	The liabilities assumed by the Purchaser included, but were not be limited to, Purchaser assuming and agreeing to fully perform and satisfy and be liable for all of the liabilities and obligations of the Company’s except for a $400 principal amount convertible note that was owed to Trilane Limited as of April 27, 2012. The note was modified in July 2012 to include a beneficial conversion feature. The conversion price of the modified note is $0.008 per share. The Company recorded a $400 beneficial conversion feature as a component of discontinued operations related to this modification. The note holder confirmed to the Company that she does not intend convert such shares as of December 31, 2012.

	A summarized statement of operations for the discontinued operations for the comparable year ended December 31, 2013 and December 31, 2012 is as follows:

		December 31,		December 31,
		2013		2012

	General and administrative		-		8
	Total operating expenses		-		8

	Interest expense		-		22
	Beneficial conversion/finance cost		-		400
	Loss from discontinued operations	$	-	$	430

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2013
Notes to Financial Statements	'
Note 11. Related Party Transactions	'
	Series A, B and C Convertible Preferred Stock – Change of Control Transaction

	On April 27, 2012, the Company was party to an agreement whereby Rockland Group, LLC, a Texas limited liability company (“Rockland”), purchased six hundred and twenty thousand (620,000) shares of Biopack Environmental Solutions, Inc. Series A Convertible Preferred Stock (“Series A Preferred Shares”), one million (1,000,000) shares of Biopack Environmental Solutions, Inc. Series B Convertible Preferred Stock (“Series B Preferred Shares”) and seven hundred ten thousand (710,000) shares of Biopack Environmental Solutions, Inc. Series C Convertible Preferred Stock (“Series C Preferred Shares”) from the holders of those shares. The Series A Preferred Shares and Series B Preferred Shares were issued prior to December 31, 2011. The Series C Preferred Shares were issued in April 2012. Together the Shares represented approximately 63% of our outstanding votes on all matters brought before the holders of our common stock for approval and, therefore, represented a change of control. Each share of Series A, B and C Convertible Preferred Stock is convertible into 5 shares of common stock on the date of this transaction.

	Intangible Asset Acquisition in Exchange for Series D Convertible Preferred Stock

	On June 25, 2012, the Company entered into a License and Asset Purchase Option Agreement (the “Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), under which TriStar Consumer Products, Inc., acquired the exclusive license to develop, market and sell, NCP’s Beaute de Maman product line, which is a line of skincare and other products specifically targeted for pregnant women. In addition, the Company acquired the exclusive license rights to develop, market and sell NCP’s formula being developed for itch suppression, which would be sold as an over-the-counter product, if successful. These licenses are for a period of up to one year, subject to earlier termination upon specified events. During the term of the license, the assets and being licensed will be run by management of NCP pursuant to a consulting agreement. As a result of these license rights the Company are now responsible for developing, marketing and selling the “Beaute de Maman” products, as well as NCP’s anti-itch formula, including all expenses, contractual arrangements, etc., related to product development, manufacturing, marketing, selling, bottling and packaging, and shipping. The Company will also receive all proceeds derived from sales of the products, other than the amounts owed to Dr. Michelle Brown, from whom NCP purchased the “Beaute de Maman” assets. Such proceeds were recorded as a reduction of general and administrative expenses. Under the arrangement with Dr. Brown she is entitled to approximately seven percent (7%) of net revenue for all products sold under the Beaute de Maman brand name and derived from formulas transferred under the agreement with NCP for a 20 year period ending December 31, 2031. In exchange for these license rights the Company agreed to issue NCP 225,000 shares of our Series D Convertible Preferred Stock. This transaction closed on June 26, 2012. Additionally, under the Agreement, in connection with the Company’s license rights and to ensure it can fulfill any immediate orders timely, the Company purchased all existing finished product of the Beaute de Maman product line currently owned by NCP. In exchange for the inventory the Company agreed to issue NCP 25,000 shares of Series D Convertible Preferred Stock. Each share is convertible into twenty five shares of common stock. The fair value of the shares amounted to $89 and was based on the closing common stock price of common stock and the conversion ratio (each share of Series D Convertible Preferred Stock is convertible into 25 shares of common stock) on the date of this transaction. The Company recorded $84 as an intangible asset and $5 as inventory on the date of the transaction.

	Issuance of Series D Convertible Preferred Stock for Cash and Services

	On June 29, 2012, the Company entered into a Stock Purchase Agreement with Rockland Group, LLC, an entity owned and controlled by Harry Pond, one the Company’s officers and directors (the “Stock Purchase Agreement”). Under the Stock Purchase Agreement, Rockland Group agreed to purchase 1,540,000 shares of our Series D Convertible Preferred Stock. The value of the shares was based upon the cash received and expenses contributed.

	The Company issued 1,046,760 shares of Series D Convertible Preferred Stock in exchange for $209 in cash. In addition, the Company issued 493,240 shares of Series D Convertible Preferred Stock in exchange for $355 of expenses contributed by Rockland on behalf of the Company (total Series D Preferred shares issued is 1,540,000). The value of the expenses contributed was based on the closing common stock price of common stock and the conversion ratio (each share of Series D Convertible Preferred Stock is convertible into 25 shares of common stock) the date of this transaction.

	Issuance of Series D Convertible Preferred Stock for Research and Development

	On July 11, 2012, the Company, entered into a Purchase and Assignment of Rights Agreement (the “Agreement”) with RWIP, LLC, an Oregon limited liability company (“RWIP”), under which the Company was assigned rights to receive certain royalty payments under previously executed agreements between RWIP and a third party. The royalty payments are equal to Twenty Percent (20%) of all net income (revenue minus expenses) received by the third party InterCore Energy, Inc., a Delaware corporation (fka. I-Web Media, Inc.) (“ICE”) from certain assets owned by ICE, as set forth in that certain asset purchase agreement between RWIP and ICE dated December 10, 2010. In exchange for these rights we agreed to issue RWIP Two Million (2,000,000) shares of our Series D Convertible Preferred Stock. The transaction closed on July 11, 2012. The fair value of the shares amounted to $700 and was based on the common stock price of common stock and the conversion ratio (each share of Series D Convertible Preferred Stock is convertible into 25 shares of common stock) on the date of this transaction. This transaction was recorded as a component of research and development expenses during 2012 because the viability of an alternative future use was uncertain.

	Consulting Agreements

	On May 15, 2012, the Company entered into a consulting agreement with Highpeak, LLC (“Highpeak”). The agreement is effective from April 1, 2012 through March 31, 2014. The Company terminated this agreement effective February 2013 and entered into an employment agreement as specified below. The Company agreed to pay Highpeak a monthly consulting fee of $10. The Company incurred $20 for the year ended December 31, 2013 and has an accounts payable balance related to this agreement of $10 as of December 31, 2013.

	On May 15, 2012, the Company entered into a consulting agreement with Rivercoach Partners LP (“Rivercoach”). The agreement is effective from April 1, 2012 through March 31, 2014. The Company terminated this agreement effective February 2013 and entered into an employment agreement as specified below. The Company agreed to pay Rivercoach a monthly consulting fee of $10. The Company incurred $20 for the year ended December 31, 2013 and has an accounts payable balance related to this agreement of $72 as of December 31, 2013.

	On June 1, 2012, the Company entered into a consulting agreement with NorthStar Consumer Products, LLC (“NCP”). The two year agreement is effective from April 1, 2012 through March 31, 2014. The Company terminated this agreement effective February 2013 and entered into an employment agreement as specified below. The Company agreed to pay NCP a monthly consulting fee of $15. The Company incurred $30 for the year ended December 31, 2013 and has an accounts payable balance related to this agreement of $262 as of December 31, 2013.

	On July 17, 2012, the Company entered into a consulting agreement with Chord Advisors, LLC (“Chord”). David Horin, the Company’s Chief Financial Officer has a significant equity partnership stake in Chord. The one year agreement was effective from July 15, 2012 through July 15, 2013. Currently the agreement is on a month to month basis. The Company has agreed to pay Chord a monthly consulting fee of approximately $13 for Mr. Horin’s services and services of his firm. The Company incurred $150 for the year ended December 31, 2013 and has an accounts payable balance related to this agreement of $113 as of December 31, 2013.

	The Company will recognize cash consulting expenses over the requisite service period pursuant to the provisions of each specific agreement.

	The Company owed reimbursable expenses, such as travel, office supplies, occupancy, etc., and accrued interest of $262 and as of December 31, 2013.

	Accounts Payable and Accrued Expensses

	During the 4th quarter of 2013, NCP forgave certain accrued expenses incurred by the Company and due to NCP. Due to the related party nature of this transaction, The Company recorded a $78 charge to additional paid in capital. As of December 31, 2013 the Company owed Daystar $50, James Barickman $3 and John Linderman 16.

	Employment Agreements

	In May 2013, the Company entered into employment agreement with Mr. Barry Starkman to serve as our Senior Vice President of Operations and the President and Chief Executive Officer of HemCon, Under the Company’s employment agreement with Mr. Starkman his employment has an initial term from May 6, 2013 until April 30, 2015 and will automatically renew for two-year terms unless terminated by the parties in accordance with the agreement. Mr. Starkman’s base salary is $250 per year with the possibility of up to 15% to 30% in incentive compensation based on meeting performance criteria to be established by us and HemCon. This employment agreement was terminated during the 1st quarter of 2014.

	In May 2013, the Company entered into employment agreement with Simon McCarthy to serve as Chief Scientist Officer of HemCon. Under the employment agreement with Mr. McCarthy his employment has an initial term from May 6, 2013 until April 30, 2015 and will automatically renew for two-year terms unless terminated by the parties in accordance with the agreement. Mr. McCarthy’s base salary is $150 per year with the possibility of up to 15% in incentive compensation based on meeting performance criteria to be established by the Company and HemCon.

	In February 2013, The Company entered into employment agreements with Mr. John Linderman to serve as President and Chief Executive Officer, Mr. James Barickman to serve as Chief Marketing Officer, Mr. Frederick A. Voight to serve as Chief Investment Officer, and Mr. Michael S. Wax to serve as Chief Development Officer.

	Under the terms of the employment agreement with Mr. Linderman, he will serve as President and Chief Executive Officer until January 31, 2018. Unless notice is given by either party of its or his intent to terminate the agreement not later than thirty (30) days prior to the end of the initial term and the end of any successive term, the agreement shall automatically renew for successive two year periods; provided however, in no event shall the term of his employment extend beyond January 31, 2023. Mr. Linderman’s duties and responsibilities will be those generally associated with a Chief Executive Officer. His compensation will be $300 per year with any additional cash or equity bonuses to be determined by the Board of Directors.

	Under the terms of the employment agreement with Mr. Barickman, he will serve as our Chief Marketing Officer until January 31, 2018. Unless notice is given by either party of its or his intent to terminate the agreement not later than thirty (30) days prior to the end of the initial term and the end of any successive term, the agreement shall automatically renew for successive two year periods; provided however, in no event shall the term of his employment extend beyond January 31, 2023. Mr. Barickman’s duties and responsibilities will be those generally associated with a Chief Marketing Officer. His compensation will be $300 per year with any additional cash or equity bonuses to be determined by our Board of Directors.

	Under the terms of the employment agreement with Mr. Voight, he will serve as our Chief Investment Officer until January 31, 2018. Unless notice is given by either party of its or his intent to terminate the agreement not later than thirty (30) days prior to the end of the initial term and the end of any successive term, the agreement shall automatically renew for successive two year periods; provided however, in no event shall the term of his employment extend beyond January 31, 2023. Mr. Voight’s duties and responsibilities will be those generally associated with a Chief Investment Officer. His compensation will be $300 per year with any additional cash or equity bonuses to be determined by our Board of Directors.

	Under the terms of the employment agreement with Mr. Wax, he will serve as our Chief Development Officer until January 31, 2018. Unless notice is given by either party of its or his intent to terminate the agreement not later than thirty (30) days prior to the end of the initial term and the end of any successive term, the agreement shall automatically renew for successive two year periods; provided however, in no event shall the term of his employment extend beyond January 31, 2023. Mr. Wax’s duties and responsibilities will be those generally associated with a Chief Development Officer. His compensation will be $300 per year with any additional cash or equity bonuses to be determined by our Board of Directors.

	During the fourth quarter of 2013, the Company converted approximately $1.1 million in Executive Officers compensation into 2,200,000 options with a fair value of $1.9 million, with a strike price of $1.00 per share. The Company recorded a gain on inducement expense of $0.8 million relating to the salary conversion. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.75%, volatility – 85.5%, expected term – 2.5 years, expected dividends– N/A.

	Related Party Notes

	During July 2012, The Company issued short term demand notes of $400 to a related party as a result of the sale of the Company’s BPAC Subsidiaries. The stated interest rate is 0.5%. The notes were modified in July 2012 to include a beneficial conversion feature. The conversion price of the modified note is $0.008 per share. The Company recorded a $400 beneficial conversion feature as a component of discontinued operations related to this modification. During the first quarter of 2013, the Company converted notes payable of approximately $32 into 4,029,200 common shares.

	During the 4th quarter of 2012, the Company issued non-convertible demand notes (formal agreements were not executed) to a related party for $125. The notes do not bear interest and were subsequently amended and converted into 33,334 shares of Series D Convertible Preferred Stock in February 2013. The Company recorded accrued interest and interest expense of $2 related to this note based upon a market interest rate of 8%.

	During the 1st quarter of 2013, the Company issued convertible demand notes to Frederick A. Voight for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

	During the 1st quarter of 2013, the Company issued convertible demand notes to Harry Pond for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

During the second quarter of 2013, the Company issued promissory notes to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $2,950. The note has an interest rate of 1.5% per month and is due on or before November 6, 2013. In connection with this promissory note, we issued DayStar Funding, LP, warrants to purchase 1,770,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the second quarter of 2013, the Company issued a promissory note with Harry Pond in the principal amount of $36. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, the Company issued to the holder warrants to purchase 21,600 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the second quarter of 2013, the Company issued a promissory note with James Linderman, the father of one of our officers and directors, in the principal amount of $100. The note has an interest rate of 1.5% per month, simple interest, and is due on or before August 6, 2013. In connection with this promissory note, we issued Mr. James Linderman warrants to purchase 50,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the second quarter of 2013, the Company issued a promissory note with James Barickman, one of our officers and directors, in the principal amount of $50. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued Mr. James Barickman warrants to purchase 25,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the second quarter of 2013, the Company issued a promissory note with John Linderman, one of our officers and directors, in the principal amount of $50. The note has an interest rate of 1.5% per month, simple interest, and is due on or before November 6, 2013. In connection with this promissory note, we issued Mr. John Linderman warrants to purchase 25,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the second quarter of 2013, the Company issued a promissory note with Frederick A. Voight, in the principal amount of $15. The note has an interest rate of 1.5% per month, simple interest, and is due on or before August 6, 2013. In connection with this promissory note, we issued Frederick A. Voight warrants to purchase 7,500 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the third quarter of 2013, the Company issued a promissory note with John Linderman, one of our officers and directors, in the principal amount of $175. The note has an interest rate of 22% per annum, simple interest, and is due on or before October 18, 2013. No warrants were issued in connection with the promissory note. The note was repaid on October 17, 2013.

During the third quarter of 2013, the Company issued promissory notes to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $470. The note has an interest rate of 1.5% per month and is due on or before November 6, 2013. In connection with this promissory note, we issued DayStar Funding, LP, warrants to purchase 282,000 shares of our common stock at an exercise price $2.74 per share, which was the fair market value of our common stock on the date of issuance. This note is currently past due.

During the fourth quarter of 2013 the Company issued promissory notes to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of 300. The note has an interest rate of 18% per annum, simple interest and is due on or before May 1, 2014. No warrants were issued in connection with the promissory note. The Company repaid $70 of this promissory note during 2013.

Preferred Stock and Note Conversions

In January 2013, the Company received a notice of conversion from Sue E. Alter, notifying the Company that she wished to convert $0.0336 of principal and interest due under that certain Tristar Wellness Solutions, Inc. Convertible Promissory Note dated April 27, 2012 into 4,200 shares of our common stock. The shares were issued to Ms. Alter, without a restrictive legend.

In February 2013, the Company received a notice of conversion from Rockland Group, LLC, one of our largest shareholders and an entity controlled by Mr. Harry Pond, one of our former officers and sole former director, notifying the Company that Rockland Group, LLC wished to convert 215,000 shares of Series A Convertible Preferred Stock into 1,075,000 shares of common stock. These shares were issued to Rockland Group, LLC, with a restrictive legend.

In February 2013, the Company received a notice of conversion from Rockland Group, LLC, one of the largest shareholders and an entity controlled by Mr. Harry Pond, one of the Company’s former officers and sole former director, notifying us that Rockland Group, LLC wished to convert 710,000 shares of Series C Convertible Preferred Stock into 3,550,000 shares of our common stock. These shares were issued to Rockland Group, LLC, with a restrictive legend.

In February 2013, the Company received a notice of conversion from Rivercoach Partners, LP, one of the largest shareholders and an entity controlled by Mr. Frederick A. Voight, notifying the Company that Rivercoach Partners, LP wished to convert 400,000 shares of Series D Preferred Stock into 10,000,000 shares of common stock. These shares were issued to Rivercoach Partner, LP, with a restrictive legend.

In February 2013, the Company received a notice of conversion from Highpeak, LLC, one of the largest shareholders and an entity controlled by Mr. Michael S. Wax, notifying the Company that Highpeak, LLC wished to convert 780,000 shares of Series D Preferred Stock into 19,500,000 shares of our common stock. These shares were issued to Highpeak, LLC, with a restrictive legend.

In February 2013, the Company received a notice of conversion from NorthStar Consumer Products, LLC, one of the largest shareholders and an entity controlled by Mr. John Linderman and Mr. Jamie Barickman, notifying us that NorthStar Consumer Products, LLC wished to convert 250,000 shares of Series D Preferred Stock into 6,250,000 shares of our common stock. These shares were issued to NorthStar Consumer Products, LLC, with a restrictive legend.

During the fourth quarter of 2012, the Company issued convertible demand notes to a related party for $125 which is convertible into 33,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 33,333 shares of Series D Convertible Preferred Stock.

During the first quarter of 2013, the Company issued convertible demand notes to a related party for $50 which is convertible into 13,333 shares of Series D Convertible Preferred Stock. The notes do not bear interest. In February 2013, the notes were converted into 13,333 shares of Series D Convertible Preferred Stock.

In February 2013, the Company issued 26,667 shares of Series D Convertible Preferred Stock to Rockland Group, LLC in exchange for $100 in cash.

In July 2013, the Company received a notice of Irrevocable Stock Power from NorthStar Consumer Products, LLC, one of the largest shareholders and an entity controlled by Mr. John Linderman and Mr. Jamie Barickman, notifying the Company that NorthStar Consumer Products, LLC wished to cancel 2,500,000 shares of Common Stock in exchange for 100,000 shares of our Series D Convertible Preferred Stock. The value of the preferred shares issued was equal to the value of the common shares cancelled therefore no loss was recorded for this transaction.

In July 2013, the Company received a notice of Irrevocable Stock from M&K Family Limited Partnership, one of the largest shareholders, notifying the Company that M&K Family Limited Partnership wished to cancel 15,750,000 shares of Common Stock in exchange for 630,000 shares of our Series D Convertible Preferred Stock. The value of the preferred shares issued was equal to the value of the common shares cancelled therefore no loss was recorded for this transaction.

In July 2013, the Company received a notice of Irrevocable Stock Power from Rivercoach Partners, LP, one of the largest shareholders and an entity controlled by Mr. Frederick A. Voight, notifying the Company that Rivercoach Partners, LP wished to cancel 6,250,000 shares of Common Stock in exchange for 250,000 shares of our Series D Convertible Preferred Stock. The value of the preferred shares issued was equal to the value of the common shares cancelled therefore no loss was recorded for this transaction.

Warrants for Research and Development

In February 2013, the Company entered into an Asset Purchase Agreement (the “HLBCDC Asset Purchase Agreement”) with HLBC Distribution Company, Inc. (“HLBCDC”) a Company controlled by Michael Wax, under which the Company exercised an option to purchase the Soft & Smooth Assets held by HLBCDC. The Soft & Smooth Assets include all rights, interests and legal claims to that certain inventions entitled “Delivery Devise with Invertible Diaphragm” as further defined in the Marketing Agreement (the “Soft and Smooth Assets”). Previously, we entered into a Marketing and Development Services Agreement (the “Marketing Agreement”) with InterCore Energy, Inc., a Delaware corporation (“ICOR”), under which the Company was retained to market and develop the Soft and Smooth Assets and were granted the exclusive option, in the Company’s sole discretion, to purchase the Soft & Smooth Assets from ICOR. Subsequently, ICOR sold the Soft and Smooth Assets to HLBCDC, transferring the rights to purchase the Soft and Smooth Assets from ICOR to HLBCDC. In exchange for the Soft and Smooth Assets the Company agreed to issue to HLBCDC warrants enabling HLBCDC to purchase One Hundred Fifty Thousand (150,000) shares of common stock at One Dollar ($1) per share, with a four (4) year expiration period. The warrants were valued at the closing price of the Company’s common stock on the date granted and amounted to approximately $100. The fair value of the 150,000 warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions: risk free interest rate - 0.88%, volatility - 85%, expected term - 4 years, expected dividend n/a.

Acquisition of Beute de Maman product Line from NorthStar Consumer Products, LLC

In February, 2013, the Company closed an Asset Purchase Agreement (the “Asset Purchase Agreement”) with NorthStar Consumer Products, LLC, a Connecticut limited liability company (“NCP”), and John Linderman and James Barickman, individuals (the “Shareholders”), under which the Company exercised an option to purchase a brand of skincare and other products specifically targeted for pregnant women (the Beaute de Maman product line), in addition to an over-the-counter itch suppression formula (together, the “Business”). Previously, the Company entered into to that certain License and Asset Purchase Option Agreement dated June 25, 2012 with NCP (the “License Agreement”), under with the Company licensed the Business from NCP and had the option to purchase the Business from NCP upon certain conditions being satisfied. As set forth in the Asset Purchase Agreement those conditions were either satisfied or renegotiated to the satisfaction of the parties and the Company exercised an option, and purchased, the Business from NCP. As consideration for the purchase of the Business the Company agreed to issue NCP, or its assignees, Seven Hundred Fifty Thousand (750,000) shares of Series D Convertible Preferred Stock. The fair value of the consideration given was $2,813 and assets received was $15 liabilities assumed $7 and such fair value was immediately impaired, due to the uncertainty of future cash flows during 2013. There was no acquired assets other than intangible assets and therefore no purchase price is being presented. The fair values for acquired intangible assets of NCP were determined by the Company using a valuation performed by an independent valuation specialist. In addition, the Company also recorded an additional $2,805 expense based on the stock valuation on the date of this transaction. This transaction was recorded as a component of research and development expenses during 2013 because the viability of an alternative future use was uncertain.

Common Stock Issued for Cash

During the fourth quarter of 2013, the Company issued for cash, 194,445 shares of common stock for approximately $175 in cash. The shares were issued to John Linderman.

Warrants for Services

During the first quarter of 2013, the Company issued 25,000 warrants to Chord Advisors, LLC with an exercise price of $0.45 and a five year term. Each warrant is exercisable into one share of common stock. The warrants were valued at the closing price of the Company’s common stock on the date granted and amounted to $20. The fair value of the 25,000 warrants was determined using the Black-Scholes Option Pricing Model with the following assumptions: risk free interest rate - 0.85%, volatility - 85%, expected term - 4 years, expected dividend n/a.

Forgiveness of Accounts Payable

During the 4th quarter of 2013, NCP forgave certain accrued expenses incurred by the Company and due to NCP. Due to the related party nature of this transaction, The Company recorded a $78 charge to additional paid in capital.

Payments to Prior Management

As of December 31, 2012, $325,970 was due to Sean Webster, our former Chief Financial Officer, Secretary, Treasurer, and a former director, and $564,320 was due to Gerald Lau, our former Chief Executive Officer, a former director of our company. This amount represents money advanced to us which had not been repaid back to them as of December 31, 2012. The amount was unsecured and bears no interest. On September 14, 2012, Rockland Group, LLC, an entity controlled by Harry Pond, one of our former officers and directors and one of our current shareholders, entered into an Assistance and Settlement Agreement with Mr. Webster and Mr. Lau under which they agreed to settle the amounts we owed to the for $32,000, which amount was due to Mr. Webster and Mr. Lau when the company got current in its periodic reporting obligations under the Securities Exchange Act of 1934, as amended. The $32,000 was paid to Mr. Webster and Mr. Lau on or about January 25, 2013, and, as a result, no further amounts are owed to Mr. Lau or Mr. Webster and they agreed to release the company from any additional amounts owed.

Intangible_Assets_Net

Intangible Assets, Net	12 Months Ended
Intangible Assets, Net	Dec. 31, 2013
Notes to Financial Statements	'
Note 12. Intangible Assets, Net	'
	On June 25, 2012, the Company entered into a License and Asset Purchase Option Agreement with NCP, under which TriStar Consumer Products, Inc., a wholly-owned subsidiary, acquired the exclusive license to develop, market and sell NCP’s Beaute de Maman product line of skincare and other products specifically targeted for pregnant women. In addition, the Company acquired the exclusive license rights to develop market and sell NCP’s formula for an over-the-counter itch suppression product. Pursuant to its June 25, 2012 agreement with NCP, the Company received an exclusive licensing rights in exchange for an aggregate of 225,000 shares of Series D Convertible Preferred Stock. The Company valued the exclusive license rights as an intangible asset for $84 as of June 25, 2012. Each share of Preferred D is convertible into twenty five shares of common stock. The fair value of the shares amounted to $84 and was based on the closing common stock price on the date of this transaction. The license rights intangible assets were fully amortized as of December 31, 2012.

	On May 6, 2013, the Company closed the acquisition of HemCon Medical Technologies Inc., an Oregon corporation (“HemCon”), pursuant to the terms of an Agreement for Purchase and Sale of Stock entered into by and between us and HemCon (the “Agreement”). The Agreement was entered into as part of HemCon’s Fifth Amended Plan of Reorganization in its bankruptcy proceeding (United States Bankruptcy Court, District of Oregon, Case No. 12-32652-elp11) and was approved by the Court as part of HemCon’s approved Plan of Reorganization. Under the Agreement, the Company purchased 100 shares of HemCon’s common stock, representing 100% of HemCon’s then-outstanding voting securities, in exchange for $3,139 in cash (the “Purchase Price”). The Purchase Price was paid to the Court and the Trustee of the bankruptcy proceeding to be distributed to HemCon’s creditors in accordance with the Plan of Reorganization.

	For the year ended December 31, 2013, intangible assets consisted primarily of patents, customer lists, non-compete arrangements and a trade name. Patents, customer lists, non-compete arrangements and a trade name acquired in business combinations under the purchase method of accounting are recorded at fair value net of accumulated amortization since the acquisition date. The intangible assets are amortized over their estimated useful life which is 4 to 16 years.

						Amortized as of		Balance as of
	Description	Life in		Price		December 31,		December 31,
	Description	Years		Price		2013		2013
	Patents		12	$	336		18	$	318
	Customer list		14		198		9		189
	Trade name		16		266		11		255
	Non-compete agreement		4		127		21		106
				$	927		59	$	867

Litigation

Litigation	12 Months Ended
Litigation	Dec. 31, 2013
Notes to Financial Statements	'
Note 13. Litigation	'
Note 13. Litigation	The Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and if such amount is not determinable, then the Company accrues the minimum of the range of probable loss. As of December 31, 2013 and 2012, there was no litigation against the Company and therefore the litigation accrual was zero.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2013
Notes to Financial Statements	'
Note 14. Fair Value Measurements	'
	The Company has adopted the provisions of ASC 820 which defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 provides guidance on how to measure certain financial assets and financial liabilities at fair value. The requirement to measure an asset as liability at fair value is determined under the U.S. GAAP.

	Certain of the Company’s assets and liabilities are considered to be financial instruments and are required to be measured at fair value in the consolidated balance sheets. Certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, short-term debt and deferred revenue are measured at cost, which approximates fair value due to the short-term maturity of these instruments. Derivative liabilities are measured at fair value.

	The Company measures fair value basis based on the following key objectives:

		•	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date;

		•	A three-level hierarchy (“Valuation Hierarchy”) which prioritizes the use of observable pricing data (Level 1 and Level 2 inputs as defined below) over unobservable pricing data (Level 3 inputs as defined below) is used in measuring value; and

		•	The Company’s creditworthiness is considered when measuring the fair value of liabilities.

	The valuation hierarchy used in measuring fair value is defined as follows:

		•	Level 1 inputs are observed inputs such as quoted prices for identical instruments inactive markets;

		•	Level 2 inputs are inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments inactive markets or quoted prices for identical or similar instruments in markets that are not active; and

		•	Level 3 inputs are unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs are unobservable. Level 3 requires significant management judgment or estimation.

	All items measures at fair value are required to be classified and disclosed as a Level 1, 2 or 3 asset or liability based on the inputs used to measure for value of an asset or liability in its entirety. An asset or liability classified as Level 1 is measured by quoted prices in active markets for identical instruments. An asset or liability classified as Level 2 is measured using significant observable inputs and an asset or liability classified as Level 3 is measured using significant unobservable inputs.

	The following table represents our assets and liabilities by level measured at fair value on a recurring basis at December 31, 2013:

	Description		Level 1	Level 2	Level 3
			None	None	None

	The following table represents our assets and liabilities by level measured at fair value on a recurring basis at December 31, 2012:

	Description		Level 1	Level 2	Level 3
			None	None	None

	The adoption of this standard did not have a material effect on the Company’s financial position, results of operations or cash flows.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2013
Notes to Financial Statements	'
15. Employee Benefit Plans	'
15. Employee Benefit Plans	In 2013 the Company adopted a qualified 401(k) profit sharing plan for eligible employees who have met certain requirements. Contributions consist of employee elective salary deferrals and employer matching deferrals. Employer matching contributions are made at the discretion of management and no such contributions were made for the year ended December 31, 2013.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
16. Commitments	'
	The Company leases manufacturing and office space and equipment under operating leases. The manufacturing and office space leases expire through 2014 and include escalation adjustments at various dates throughout the lease terms. The equipment operating leases expire through 2016. Future minimum lease payments under these leases for the years ending December 31 are as follows:

	Years ending December 31:

	2014	$	524
	2015		141
	2016		25

		$	690

	The Company re negotiated its lease agreement on its manufacturing facility premises in February of 2013 following a request by the landlord to lift the stay afforded by Bankruptcy Protection. This modification to the lease term which inserts six month break clauses and reduces the term of the lease by 6 months has been included in the above.

	Total rent expense amounted to $524 and $0 for the years ended December 31, 2013 and 2012.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Notes to Financial Statements	'
Note 17. Subsequent Events	'
Note 17. Subsequent Events	During the first quarter of 2014 the Company issued a promissory note to a third party, in the principal amount of $780. The note has an interest rate of 21% per annum, simple interest and is due on or before November 30, 2014. In connection with this promissory note, the Company issued warrants to purchase 780,000 shares of our common stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies Policies	'
Basis of Presentation and Principles of Consolidation	'
	The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries. All intercompany balances and transactions have been eliminated.

Cash and Cash Equivalents	'
	Cash consists of funds deposited in checking accounts. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high quality of the institutions that have custody of the Company’s funds. The Company has not incurred any losses on such accounts.

Accounts Receivable	'
	The Company extends credit to its customers in the normal course of business and performs ongoing credit evaluations of its customers. Accounts receivable are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer's current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of an allowance for doubtful accounts of $8 and $0, at December 31, 2013 and December 31, 2012, respectively.

Use of Estimates	'
	In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments upon issuance, and estimating the useful lives of depreciable assets and whether impairment charges may apply.

Revenue Recognition	'
	Product Sales Revenue

	The Company recognizes product sales revenue when there is persuasive evidence of an arrangement, prices are fixed and determinable, the product is shipped or delivered, title and risk of loss have passed to the customer, and collection is reasonably assured. Certain of its product sales are made to distributors. The Company's distributor arrangements do not provide distributors with product return rights or pricing adjustments. The Company recognizes product sales to distributors on a sell-in basis, when the product is delivered

	Deferred Revenue

	The Company defers nonrefundable up-front payments received from distributors. These fees are recognized on a straight-line basis over the contractual term of the related contract.

Inventories	'
	Inventories are stated at the lower of standard cost (which approximates average cost) or market.
Property and Equipment	'
	Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided using the straight-line method for financial reporting purposes based on the estimated useful lives of the various assets ranging from three to ten years. Maintenance and repair costs are charged to current earnings. Upon disposal of assets, the costs of assets and the related accumulated depreciation are removed from the accounts. Gains or losses are reflected in current earnings.

Intangible assets	'
	Intangible assets consist of patents, customer lists, non-compete arrangements and a trade name. Patents, customer lists, non-compete arrangements and a trade name acquired in business combinations under the purchase method of accounting are recorded at fair value net of accumulated amortization since the acquisition date. Amortization is calculated using the straight line method over the estimated useful lives at the following annual rates:

		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16

	The Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined based on discounted cash flows.

Other Receivables and Current Liabilities Related to Assets Sold	'
	Prior to the Company acquisition of HemCon, on February 6, 2013, HemCon concluded an asset sale with Bard Access Systems for its GuardIVa™ product plus associated intellectual property and trademark for $4,500 following on from a license and supply agreement in October 2012 for $500. GuardIVa™ has been classified as a discontinued operation in the Consolidated Statement of Operations. This sale and the proceeds which were realized facilitated the Company in emerging from Chapter 11 Bankruptcy. An amount of $1.5 million remains outstanding as deferred consideration which is payable on achieving certain regulatory requirements. This deferred consideration will be paid to the Secured Creditors under the bankruptcy case 12-32652-ELP11 pursuant to the HemCon Sale and purchase agreement on receipt of same. GuardIVa™ is a hydrophilic foam based IV site dressing for use at Catheter insertion sites. The dressing incorporates HemCon micro dispersed oxidized cellulose technology an active hemostatic ingredient along with CHG a generic antibacterial agent.

Accumulated Other Comprehensive Income	'
	Comprehensive income is defined as the change in equity of a company during the period resulting from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. The primary difference between net income and comprehensive income for the Company results from foreign currency translation adjustments. Accumulated other comprehensive loss was $19 for the period ended December 31, 2013 and $0 at December 31, 2012. The financial position of foreign subsidiaries is translated using the exchange rates in effect at the end of the period, while income and expense items are translated at average rates of exchange during the period. The net losses resulting from foreign currency transactions are recorded in the consolidated statements of operations in the period incurred were $19 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.

Concentration of Source of Materials	'
	The Company uses a raw material that must meet specific quality standards in its production process, which is currently purchased from one vendor. The Company mitigates the risk to its production process through purchasing quantities sufficient to meet its production needs in the near term and by having identified alternative sources of supply of an equivalent standard should they become necessary.

Stock-Based Compensation	'
	Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit.

Segment Reporting	'
	The Company operates as one segment, in which management uses one measure of profitability. The Company is managed and operated as one business. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments.

Accounting for Warrants	'
	The Company accounts for the issuance of common stock purchase warrants issued in connection with equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

	The Company assessed the classification of its common stock purchase warrants as of the date of each transaction and determined that such instruments met the criteria for equity classification. The warrants are reported on the consolidated balance sheet as a component of stockholders’ equity at fair value using the Black-Scholes valuation method.

Income Taxes	'
	The Company adopted the provisions of ASC 740-10, which prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return.

	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2013. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

	The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations.

Loss per Share	'
	Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares (including redeemable shares) plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.

Recently Issued Accounting Pronouncements	'
	Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a significant effect to the accompanying consolidated financial statements.
Revenue Concentrations	'
	The Company considers significant revenue concentrations to be counterparties who account for 10% or more of the total revenues generated by the Company during the period. For the year ended December 31, 2013, the amount of revenue derived from counterparties representing more than 10% of our total revenues was 13%. As of December 31, 2013 Two customers owed a total of 33% of accounts receivable.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2013
Summary Of Significant Accounting Policies Tables	'
Estimated useful lives	'
	Amortization is calculated using the straight line method over the estimated useful lives at the following annual rates:

		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
Business Combinations (Tables)	Dec. 31, 2013
Business Combinations Tables	'
Estimates of fair value	'
	The purchase price allocation is based on estimates of fair value as follows (in thousands):

	Accounts receivables	$	653
	Other receivables		1,500
	Inventory		1,410
	Other current assets		23
	Prepaid expenses		156
	Fixed assets		1,193
	Accounts payable and accrued expenses		(341	)
	Current liabilities related to assets held for sale		(1,500	)
	Deferred revenue		(882	)
	Patents		336
	Customer list		198
	Trade name		266
	Non-compete agreement		127
	Total acquisition cost allocated	$	3,139

Useful lives	'
	The useful lives of the acquired intangibles are as follows:

		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16
Acquisition financial information	'
	The following unaudited pro forma financial information presents results as if the acquisition of HemCon had occurred on January 1, 2013 and January 1, 2012 (in thousands):

	Year Ended December 31 ,
	(Unaudited)	2013			2012

	Total revenue	$	5,469			$	4,943
	Net loss	$	(13,336	)		$	(9,751	)

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2013
Inventories Tables	'
Inventories	'
	Inventories, net consist of the following at December 31, 2013 and December 31, 2012 (in thousands):

		December 31,
		2013		2012
	Raw materials	$	318	$	-
	Work in Progress		251		-
	Finished Goods		575		12
		$	1,144	$	12

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2013
Property And Equipment Tables	'
Property and Equipment	'
	Property and equipment consist of the following at December 31, 2013 and December 31, 2012 (in thousands):

		Estimates Useful Life	December 31,
		(Years)	2013			2012
	Manufacturing Equipment	10-Jul	$	623		$	-
	Leasehold Improvements	7	$	520			-
	Office Furniture and Equipment	7-Mar	$	32			-
	Computer Equipment and Software	5-Jan	$	12			1
	Construction in Progress			6			-
				1,193			1
	Less: Accumulated Depreciation, amortization and impairments			(196	)		-
			$	997		$	1

Loans_Payable_Tables

Loans Payable (Tables)	12 Months Ended
Loans Payable (Tables)	Dec. 31, 2013
Loans Payable Tables	'
Schedule of Short term loans	'

		December 31,		December 31,
		2013		2012
	Short-term notes (net of debt discount $497 and $0 as December 31, 2013 and December 31, 2012, respectively)	$	714	$	50
	Short-term notes - related party		3,970		525
		$	4,684	$	575

Schedule of Long term loans	'
		December 31,		December 31,
		2013		2012
	Convertible notes	$	356		-
			356	$	-

Deferred_Income_Taxes_Tables

Deferred Income Taxes (Tables)	12 Months Ended
Deferred Income Taxes (Tables)	Dec. 31, 2013
Deferred Income Taxes Tables	'
Deferred tax assets and liabilities	'
	The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2013 and 2012 are comprised of the following:

		As of			As of
		December 31,			December 31,
		2013			2012
	Deferred tax asset
	Net operating loss carryovers	$	2,184		$	255
	Intangible asset amortization		29			-
	Stock-based compensation		1,721			-
	Amortization of debt discount		949			-
	Inducement expenses		313			-
	Total deferred tax assets		5,196			255
	Valuation Allowance		(5,196	)		(255	)
	Deferred tax asset, net of allowance	$	-		$	-
Expected tax expense (benefit), in percentages	'
	The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:

		For year ended			For year ended
		31-Dec-13			31-Dec-12
	Statutory federal income tax rate		-34	%		-34	%
	State taxes, net of federal tax benefit		-5	%		0	%
	Meals & entertainment		0.09	%		0	%
	Inputed interest		0.1	%		0	%
	Valuation Allowance		38.9	%		34	%
	Income tax provision (benefit)		0	%		0	%
Expected tax expense (benefit)	'
		For year ended			For year ended
		31-Dec-13			31-Dec-12
	Federal
	Current	$	-		$	-
	Deferred		(4,530	)		255
	State
	Current		-			-
	Deferred		(666	)		-
	Change in valuation allowance		5,143			(255	)
	Income tax provision (benefit)	$	-		$	-

Discontinued_Operation_Tables

Discontinued Operation (Tables)	12 Months Ended
Discontinued Operation (Tables)	Dec. 31, 2013
Discontinued Operation Tables	'
Discontinued operations	'
	A summarized statement of operations for the discontinued operations for the comparable year ended December 31, 2013 and December 31, 2012 is as follows:

		December 31,		December 31,
		2013		2012

	General and administrative		-		8
	Total operating expenses		-		8

	Interest expense		-		22
	Beneficial conversion/finance cost		-		400
	Loss from discontinued operations	$	-	$	430

Intangible_Assets_Net_Tables

Intangible Assets, Net (Tables)	12 Months Ended
Intangible Assets, Net (Tables)	Dec. 31, 2013
Intangible Assets Net Tables	'
Schedule of intangible assets	'
	The intangible assets are amortized over their estimated useful life which is 4 to 16 years.

						Amortized as of		Balance as of
	Description	Life in		Price		December 31,		December 31,
	Description	Years		Price		2013		2013
	Patents		12	$	336		18	$	318
	Customer list		14		198		9		189
	Trade name		16		266		11		255
	Non-compete agreement		4		127		21		106
				$	927		59	$	867

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2013
Fair Value Measurements Tables	'
Assets and liabilities by level measured at fair value on a recurring basis	'
	The following table represents our assets and liabilities by level measured at fair value on a recurring basis at December 31, 2013:

	Description	Level 1	Level 2	Level 3
		None	None	None

	The following table represents our assets and liabilities by level measured at fair value on a recurring basis at December 31, 2012:

	Description	Level 1	Level 2	Level 3
		None	None	None

Commitments_Tables

Commitments (Tables)	12 Months Ended
Commitments (Tables)	Dec. 31, 2013
Commitments Tables	'
Future minimum lease payments	'
	Future minimum lease payments under these leases for the years ending December 31 are as follows:

	Years ending December 31:

	2014	$	524
	2015		141
	2016		25

		$	690

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
Summary of Significant Accounting Policies (Details)	Dec. 31, 2013
Patents [Member]	'
Intangible asset useful life	'12 years
Customer Lists [Member]	'
Intangible asset useful life	'14 years
Non-compete Agreements [Member]	'
Intangible asset useful life	'4 years
Trade Name [Member]	'
Intangible asset useful life	'16 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies Details Narrative	'	'
Allowance for doubtful accounts	$8	$0
Accumulated other comprehensive income	19	0
Foreign currency transactions	$19	$0
Counterparties representing more than 10% of our total revenues	23.00%	'
Two customer owed accounts receivable	33.00%	'

Going_Concern_and_Managements_1

Going Concern and Management's Plans (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Going Concern And Managements Plans Details Narrative	'	'
Accumulated deficit	$224,442	'
Working capital deficit	5,487	'
Net loss	$12,647	$2,248

Business_Combinations_Details

Business Combinations (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Business Combinations Details	'
Accounts receivables	$653
Other receivables	1,500
Inventory	1,410
Other current assets	23
Prepaid expenses	156
Fixed assets	1,193
Accounts payable and accrued expenses	-341
Current liabilities related to assets held for sale	-1,500
Deferred revenue	-882
Patents	336
Customer list	198
Trade name	266
Non-compete agreement	127
Total acquisition cost allocated	$3,139

Business_Combinations_Details_

Business Combinations (Details 1)	12 Months Ended
Business Combinations (Details 1)	Dec. 31, 2013
Patents [Member]	'
Intangible asset useful life	'12 years
Customer Lists [Member]	'
Intangible asset useful life	'14 years
Non-compete Agreements [Member]	'
Intangible asset useful life	'4 years
Trade Name [Member]	'
Intangible asset useful life	'16 years

Business_Combinations_Details_1

Business Combinations (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combinations Details 2	'	'
Total revenue	$5,469	$4,943
Net loss	($13,336)	($9,751)

Business_Combinations_Details_2

Business Combinations (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combinations Details Narrative	'	'
Acquisition charges	$100	'
Additional interest expense	$100	$100

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventories Details	'	'
Raw Materials	$318	'
Work In Progress	251	'
Finished Goods	575	12
Inventories net	$1,144	$12

Inventories_Details_Narrative

Inventories (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventories Details Narrative	'	'
Reserve for obsolescence	$251	$0

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment, Gross	$1,193	$1
Less: Accumulated Depreciation, amortization and impairments	-196	'
Property and Equipment, Net	997	1
Manufacturing Equipment [Member]	'	'
Property and Equipment, Gross	623	'
Manufacturing Equipment [Member] \| Minimum [Member]	'	'
Estimates Useful Life	'7 years	'
Manufacturing Equipment [Member] \| Maximum [Member]	'	'
Estimates Useful Life	'10 years	'
Leasehold Improvements [Member]	'	'
Estimates Useful Life	'7 years	'
Property and Equipment, Gross	520	'
Office Furniture and Equipment [Member]	'	'
Property and Equipment, Gross	32	'
Office Furniture and Equipment [Member] \| Minimum [Member]	'	'
Estimates Useful Life	'3 years	'
Office Furniture and Equipment [Member] \| Maximum [Member]	'	'
Estimates Useful Life	'7 years	'
Computer Equipment and Software [Member]	'	'
Property and Equipment, Gross	12	1
Computer Equipment and Software [Member] \| Minimum [Member]	'	'
Estimates Useful Life	'1 year	'
Computer Equipment and Software [Member] \| Maximum [Member]	'	'
Estimates Useful Life	'5 years	'
Construction in Progress [Member]	'	'
Property and Equipment, Gross	$6	'

Property_and_Equipment_Details1

Property and Equipment (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property And Equipment Details Narrative	'	'
Depreciation expense	$196	$0

Loans_Payable_Details

Loans Payable (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Loans Payable Details	'	'
Short term notes	$714	$50
Short term notes - related party	3,970	525
Loans Payable	$4,684	$575

Loans_Payable_Details_1

Loans Payable (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Long term loans	'	'
Convertible notes	$356	'
Convertible notes, Total	$356	'

Loans_Payable_Details_Narrativ

Loans Payable (Details Narrative) (USD $)	12 Months Ended		3 Months Ended	12 Months Ended	3 Months Ended			12 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
			Promissory Note, 2013 Activity [Member]	Promissory Note, 2013 Activity [Member]	Original Terms of Notes [Member]	HemCon [Member]	DayStar Funding, LP [Member]	DayStar Funding, LP [Member]	Series D Convertible Preferred Stock
									Loans Payable [Member]
Convertible demand notes to third party	'	'	'	'	'	'	'	'	$50
Convertible demand notes to related party	'	'	'	'	4	'	'	'	125
Notes Convertible into preferred shares to third party	'	'	'	'	'	'	'	'	13,333
Notes Convertible into preferred shares to related party	'	'	'	'	500,000	'	'	'	33,333
Payment for the acquisition	'	'	'	'	'	400	'	'	'
Principal amount	300	'	1,100	1,100	'	'	300	300	'
Interest rate	'	'	21.00%	21.00%	'	'	18.00%	18.00%	'
Maturity Date	'	'	'Due on or before November 30, 2014	'	'	'	'Due on or before May 1, 2014	'	'
Repaid promissory note	'	'	'	'	'	'	'	70	'
Risk free interest rate	'	'	1.39%	'	'	'	'	'	'
Expected volatility rate	'	'	85.80%	'	'	'	'	'	'
Expected term	'	'	'4 years	'	'	'	'	'	'
Expected dividend	'	'	'	'	'	'	'	'	'
Amortization expense on the debt discount	2,002	'	'	56	'	'	'	'	'
Debt discount related to the warrants	'	'	556	'	'	'	'	'	'
Market interest rate	8.00%	8.00%	'	'	'	'	'	'	'
Accrued interest based on the stated rate	0.50%	0.50%	'	'	'	'	'	'	'
Convertible debentures and interest expense	$31	$34	'	'	'	'	'	'	'

Stockholders_Equity_Details_Na

Stockholders' Equity (Details Narrative) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Original Terms of Notes [Member]

Series D Preferred Convertible Member

Series D Convertible Preferred Stock

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series C Preferred Stock [Member]

Detachable Warrants One [Member]

Warrants for Services [Member]

Fair value of the consideration

$2,813

Asset received

Liabilities assumed

Additional paid in capital

18,823

8,939

Preferred Shares convertible into number of common shares

2,330,000

4,216,667

3,790,000

Converted common shares

11,650,000

105,416,675

94,750,000

Preffered shares

405,000

1,000,000

Convertible warrants

5,782,600

Convertible demand notes to third party

Convertible demand notes to related party

125

Notes Convertible into preffered shares to third party

13,333

Notes Convertible into preffered shares to related party

500,000

33,333

Company issued for shares

194,445

Company issued for cash

175

Relative fair value of the detachable Warrants

556

Issued warrants, Shares

1,000,000

Issued warrants exercise prices

$1.19

Risk free interest rate

1.39%

1.75%

Volatility

85.80%

85.50%

Expected term

'4 years

'2 years 6 months

Expected dividend

Value of convertible warrants

1,100

Converted options

2,200,000

Fair value of converted options

$1,900

Strike price

Deferred_Income_Taxes_Details

Deferred Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred tax asset	'	'
Net operating loss carryovers	$2,184	$255
Intangible asset amortization	29	'
Stock-based compensation	1,721	'
Amortization of debt discount	949	'
Inducement expenses	313	'
Total deferred tax assets	5,144	255
Valuation Allowance	-5,144	-255
Deferred tax asset, net of allowance	'	'

Deferred_Income_Taxes_Details_

Deferred Income Taxes (Details 1)	12 Months Ended
Deferred Income Taxes (Details 1)	Dec. 31, 2013	Dec. 31, 2012
Deferred Income Taxes Details 1	'	'
Statutory federal income tax rate	-34.00%	-34.00%
State taxes, net of federal tax benefit	-5.00%	0.00%
Meals & entertainment	0.09%	0.00%
Inputed interest	0.10%	0.00%
Valuation Allowance	38.90%	34.00%
Income tax provision (benefit)	0.00%	0.00%

Deferred_Income_Taxes_Details_1

Deferred Income Taxes (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Federal	'	'
Current	'	'
Deferred	-4,530	255
State	'	'
Current	'	'
Deferred	-666	'
Change in valuation allowance	5,143	-255
Income tax provision (benefit)	'	'

Deferred_Income_Taxes_Details_2

Deferred Income Taxes (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred Income Taxes Details Narrative	'	'
Cumulative net operating loss carry forward	$5,601	$730
Net operating loss carry forward expiration period	'2033	'

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Discontinued Operations Details	'	'
General and administrative	'	$8
Total operating expenses	'	8
Interest expense	'	22
Beneficial conversion/finance cost	'	400
Loss from discontinued opertations	'	$430

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013
Reimbursable expenses	'	$262
Additional paid in capital	78	78
Conversion of notes payable to common stock, value	'	32
Conversion of notes payable to common stock, shares	'	4,029,200
Repayment of promissory notes	'	70
Principal amount	300	300
Interest rate per annum	18.00%	18.00%
Share issued for cash, shares	194,445	'
Share issued for cash, values	175	'
DayStar Funding, LP [Member]	'	'
Additional paid in capital	50	50
Principal amount	300	300
John Linderman [Member]	'	'
Additional paid in capital	16	16
James Barickman [Member]	'	'
Additional paid in capital	3	3
Highpeak, LLC [Member]	'	'
Consulting fee incurred	'	20
Accounts payable balance	10	10
Rivercoach Partners LP [Member]	'	'
Consulting fee incurred	'	20
Accounts payable balance	72	72
NorthStar Consumer Products, LLC [Member]	'	'
Consulting fee incurred	'	30
Accounts payable balance	262	262
Chord Advisors, LLC [Member]	'	'
Consulting fee incurred	'	150
Accounts payable balance	$113	$113

Intangible_Assets_Net_Details

Intangible Assets, Net (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Intangible assets, Price	$927
Intangible assets, Amortized	59
Intangible asset, balance	867
Patents [Member]	'
Intangible assets, Life in Years	'12 years
Intangible assets, Price	336
Intangible assets, Amortized	18
Intangible asset, balance	318
Customer Lists [Member]	'
Intangible assets, Life in Years	'14 years
Intangible assets, Price	198
Intangible assets, Amortized	9
Intangible asset, balance	189
Patents [Member]	'
Intangible assets, Life in Years	'16 years
Intangible assets, Price	266
Intangible assets, Amortized	11
Intangible asset, balance	255
Non-compete Agreements [Member]	'
Intangible assets, Life in Years	'4 years
Intangible assets, Price	127
Intangible assets, Amortized	21
Intangible asset, balance	$106

Intangible_Assets_Net_Details_

Intangible Assets, Net (Details Narrative)	12 Months Ended
Intangible Assets, Net (Details Narrative)	Dec. 31, 2013
Intangible Assets Net Details Narrative	'
Intangible assets amortized over estimated useful life	'4 to 16 years

Litigation_Details_Narrative

Litigation (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Litigation Details Narrative	'	'
Litigation accrual	$0	$0

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Level 1 [Member]	'	'
Assets and liabilities measured at fair value on recurring basis	'	'
Level 2 [Member]	'	'
Assets and liabilities measured at fair value on recurring basis	'	'
Level 3 [Member]	'	'
Assets and liabilities measured at fair value on recurring basis	'	'

Commitments_Details

Commitments (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Commitments Details	'
2014	$524
2015	141
2016	25
Future minimum lease payments	$690

Commitments_Details_Narrative

Commitments (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Commitments Details Narrative	'	'
Total rent expense	$524	$0